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[57] ABSTRACT 
Phosphonic acid agents are synthesized and characterized 
Which are potent inhibitors of angiogenesis, tumorigenesis 
and metalloproteinase activity. Their method of use for the 
inhibition of angiogenesis and metalloproteinase and the 
treatment of tumors is also shoWn. 
8 Claims, No Drawings 
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1 
PHOSPHONATED AGENTS AND THEIR 
ANTIANGIOGENIC AND 
ANTITUMORIGENIC USE 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority under 35 U.S.C. § 120 
from Ser. No. 08/899,996, ?led Jul. 24, 1997 of Which this 
application is a Continuation-In-Part, noW abandoned. 
FIELD OF THE INVENTION 
The present invention relates to phosphonic acid agents 
that are potent inhibitors of angiogenesis and tumorigenesis. 
BACKGROUND ART 
Angiogenesis is an essential component of tumor groWth 
and metastasis. As revieWed by Folkman (1985), the groWth 
of solid tumors is dependent on angiogenesis. Typically 
tumors do not groW beyond a siZe of 2—3 mm unless they are 
able to stimulate the groWth of neW capillaries from the 
existing vascular netWork. Additionally, the neW blood ves 
sels provide an essential entry route to the vasculature for 
metastasis of tumor cells. Cell division in endothelial cells 
is sloW, With a turnover time of years rather than days or 
hours (Denekamp, 1984). 
HoWever, vascular endothelial cells undergo rapid prolif 
eration With turnover times of a feW days during the groWth 
of neW capillaries. Angiogenesis-dependent diseases such as 
diabetic retinopathy, psoriasis, arthritis, hemangiomas and 
tumor groWth and metastasis are characteriZed by uncon 
trolled groWth of capillary blood vessels. The most striking 
example of uncontrolled angiogenesis is associated With 
tumor groWth (Folkman, 1985). 
Accordingly, the search for angiogenesis inhibitors Was 
stimulated by the concept of “antiangiogenic therapy”. In its 
simplest terms, antiangiogenic therapy sought a putative 
inhibitor of blood vessel groWth in the believe that such an 
inhibitor might be therapeutic by limiting tumor groWth and 
further such an inhibitor Would be non-toxic because angio 
genesis is normally infrequent (Folkman, 1992). A number 
of different factors can stimulate angiogenesis in vivo. These 
angiogenic factors, such as basic ?broblast groWth factor 
(bFGF), vascular endothelial groWth factor (VEGF), 
platelet-derived groWth factor (PDGF) and transforming 
groWth factor 0t and [3, can be released from the tumor cells 
themselves and by other cells such as macrophages and 
endothelial cells (Folkman, 1992). 
The mechanisms by Which tumors induce angiogenesis 
are very complex and involve many pathWays, an angio 
genesis inhibitor could be directed against any of the com 
ponents of the angiogenic cascade. The identi?cation of 
compounds that block neovasculariZation has a long stand 
ing interest. A number of inhibitory extracts have been 
prepared from avascular tissues, such as cartilage (Braunhut 
et al., 1989). One such method of treating tumors has been 
by the administration of suramin. HoWever, it is believed 
that suramin may have adverse effects in large dosages. 
Accordingly, a continuing need exists for agents that 
overcome the de?ciencies of prior antiangiogenic 
compounds, including suramin. There is also a need for 
antiangiogenic agents that have a reduced toxicity to a 
recipient and increase inhibition of angiogenesis and tum 
origenesis. 
SUMMARY OF THE INVENTION 
It is an object of the present invention to provide novel 
phosphonic acid substituted agents and pharmaceutical com 
positions containing said agents. 
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2 
In an embodiment, the invention provides methods of 
treating tumors comprising the steps of administering an 
effective amount of a phosphonic acid substituted agent to a 
patient in need of said treatment. 
In another embodiment the invention provides a method 
of inhibiting angiogenesis comprising the steps of adminis 
tering an effective amount of a phosphonic acid substituted 
agent to a patient in need of said treatment. 
In satisfaction of the foregoing objects and advantages, 
the present invention provides phosphonic acid derivatives 
of agents and methods for their preparation. 
The invention also provides pharmaceutical compositions 
and methods for use of the compositions as potent inhibitors 
of angiogenesis and tumorigenesis. 
In parent application Ser. No. 08/889,996, the compounds 
of the invention Were referred to as naphthylureas. HoWever, 
the more appropriate class of the agents are as described 
herein. 
The above and other objects of the invention Will become 
readily apparent to those of skill in the relevant art from the 
folloWing detailed description, tables and formulas, Wherein 
only the preferred embodiments of the invention are shoWn 
and described, simply by Way of illustration of the best mode 
of carrying out the invention. 
DESCRIPTION OF THE INVENTION 
The present invention provides a novel group of phos 
phonic acid agents Which Were synthesiZed and character 
iZed. This unique group of compounds are potent inhibitors 
of angiogenesis, equipotent to 40 times greater than suramin. 
In addition, results shoW that phosphonic acid agents dem 
onstrate loWer toxicity and exert their antiangiogenic effect 
via a different mechanism than suramin. 
Without subscribing to any particular theory, it is believed 
that phosphonic acid agents are potent inhibitors of angio 
genesis and that the antiangiogenic effect is mediated 
through a speci?c effect of these compounds upon prolifer 
ating endothelial cells. The mechanism for inhibition of 
angiogenesis by the phosphonic acid agents may involve 
inhibition of DNA replication, cell signaling and/or energy 
production. 
Furthermore, the antiangiogenic and endothelial cell 
groWth inhibiting activity of the phosphonic acid agents is 
not primarily related to the inhibition of binding of the 
angiogenic groWth factors to their receptors on the endot 
helial cell surface as has been demonstrated for suramin. 
The ?ndings that this unique group of phosphonic acid 
agents have more potent antiangiogenic activity, are less 
toxic than suramin, and are metaboliZed and cleared in hours 
rather than Weeks suggest that these agents are potent 
therapeutic agents for “angiogenesis-dependent” diseases. 
These diseases include diabetic retinopathy, arthritis, 
psoriasis, tumor groWth and metastasis. 
The commercial advantage of the phosphonic acid agents 
resides is their loWer toxicity and enhanced antiangiogenic 
activity. The experiments presented illustrate the potent 
inhibition of angiogenesis by the use of the phosphonic acid 
agents to inhibit the groWth of various immortaliZed human 
cancer cell lines. Further experiments provide in vivo mouse 
toxicity studies and neurotoxicity in vitro assays. 
Additionally, animal studies are presented in Which SCID or 
nude mice are implanted With human tumors and then 
treated With the selected phosphonic acid agents. 
According to the present invention, phosphonic acid 
agents, described by structural formula and chemical name, 
are potent inhibitors of angiogenesis and/or tumorigenesis 
While exhibiting loW toxicity. 
The present invention provides a preferred novel class of 
phosphonic acid group substituted agents Which are de?ned 
by the folloWing formulae: 
3 
wherein 
P is a phosphonic group or a phosphonic salt, as for 
example, a phosphonic group substituted With one or more 
alkali metals; 
Y is —OCO—, —NR1CO—, or —CON(R1)R2—; 
R1 is H, CH2CO2H, or substituted or unsubstituted alkyl; 
R2 is substituted or unsubstituted alkyl, aryl, or arylalkyl; 
6,096,730 
Q1 and Q2 are substituted or unsubstituted aryl groups; 
CSNH—; provided that When K is H, j is 0; 
R3 is a substituted or unsubstituted aryl group; 
j is 0, 1, or 2; 
n1 and n2 are independently 0, 1, or 2; and 
m1 and m2 are independently an integer from 1 to 4. 
Embodiments of the phosphonic acid agents of the present 
invention comprise compounds of the formulae: 
N 
| 
H 
A) 
10 
15 
20 
25 
4 
-continued 
B) 
| \ 
—fYTP) 1111 
// 
R6 
Wherein 
Y, P, n1, n2, m1, m2 R3 are as de?ned above; 
B is CO, CS, CO—R3—CO, or CS—R3—CS; 
R4 and R5 are independently H or a substituted or unsub 
stituted alkyl group; 
R6 is H, or NCOR7; and 
R7 is aryl, substituted aryl, or nitro substituted aryl. 
Preferred phosphonic acid agents of the invention are set 
forth beloW in Tables 1—3, Which tables provide chemical 
formulae, molecular Weights, and properties of the com 
pounds including some embryo and inhibition data. 
TABLE 1 
The code number, formula, molecular Weight, synthesis method, basic structure and substitutions 
at positions 2 3 and 4 for the phosphonic acid agents With small urea bridges are indicated. 
1‘ l‘ 
2 N N 2 
3 T 3 
4 O 4 
5 5 
Synthesis Substitution at Position # % 
Code Formula Mol Wt Method —2 —3 —4 Em Ih 
NE 158 C‘13H12N2O7P2Na2 416.2 B, C H PO3HNa H 23 0 
NE 161 C‘13H12N2O7P2Na2 416.2 B, C H H PO3HNa 21 53 
NE 473 CMHUNZOUPZNa2 504.2 G, B, C, Fb OCOPO3HNa H H 20 21 
NE 426 CMHUNZOUPZNa2 504.2 G, B, C, Fb H OCOPO3HNa H 22 39 
NE 392 CMHUNZOUPZNa2 504.2 G, B, C, Fb H H OCOPO3HNa 24 6 
NE 474 CUHMNZOUPZNa2 532.2 G, B, C, Fb H CH3 OCOPO3HNa 21 12 
NE 427 CBHMN4O9P2Na2 502.2 Fa, Fb, B, C H NHCOPO3HNa H 
NE 428 CBHMN4O9P2Na2 502.2 Fa, Fb, B, C H H NHCOPO3HNa 
NE 433 C21H22N4O13P2Li2 614.3 A,B C H Al H 
NE 434 C21H22N4O13P2Li2 614.3 H H Al 
Where Em represents Embryos; Ih: represents Inhibition; and A1 is 
CONCH2PO3HLi 
CHZCOZH 
60 
65 
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TABLE 2 
The code number, formula, molecular Weight, synthesis method, basic structure and substitutions 
at positions 2, 3, 4, 4' and X for seven phosphonic acid agents With big urea bridges are indicated. 
Code Formula Mol Wt 
4 O O 4 
3 3 
2 N X N 2 
H db H 
T T 
H H 
Synthesis Substitution at Position # % 
Method 3 4 X Em Ih 
NF O69 C27H22N4O9P2Na2 654.4 A, B, C, D PO3HNa H O 26 66 
NF 681 C27H22N4O9P2Na2 654.4 A, B, C, D H PO3HNa O 28 100 
NF 162 C27H22N4O8P2SNa2 670.5 A, B, C, D H PO3HNa S 
4 O O 4 
3 N N 3 
2 N T N 2 
H 4' O 4' H 
Synthesis Substitution at Position # % 
Method 2 3 4 4' Em Ih 
NF O68 C27H22N2O9P2Na2 654.4 A, B, C, D H PO3HNa H H 27 0 
NF O67 C27H22N2O9P2Na2 654.4 A, B, C, D H H PO3HNa H 25 62 
NF 540 C31H3ON4O9P2Na2 710.5 Ba, Ec, B, A, B, C H H CH2PO3HNa CH3 
NF 544 C33H38N4O15P4 854.6 Ea, Ec, B, A, B, C CH2PO3H2 H CH2PO3H2 CH3 
TABLE 3 
The code number, formula, molecular Weight, synthesis 
method, and chemical structures of phosphonic acid agents are indicated. 
Synthesis 
Method Compound 
A o 
NaHO P 
3 PII 
H N \/\PO3HNa 
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TABLE 3-continued 
The code number, formula, molecular Weight, synthesis 
method and chemical structures of phosphonic acid agents are indicated. 
Synthesis 
Method Compound 
A, B, C N02 
0 NH 
H H 
N N 
O o o NaHO3P 
A, B, A, 
B, C PII O 
N21203P N 
T 
O H 
NF O50 C41H3DN6O11P2Na4(936.62) 
A, B, A, H 
B, c | 
N o 
o 
N 
T 
CH3 H 
T 
O 
2 
Synthesis of Phosphonic Acid Agents 
The syntheses of the phosphonic acid agents of this 
invention are shown in process Schemes 1 and 2 beloW. 
General procedures for the syntheses are described under 
Synthetic Methods A—G. Synthetic methods used for the 
synthesis of the individual phosphonic acid agents are listed 
in Tables 2—3. 
The phosphonic acid agents synthesized herein can be 
divided into three general groups. Table 1 shoWs phosphonic 
acid agents With small urea bridges. The basic structural 
formula, the chemical substitutions at each position, formula 
and molecular Weight, are shoWn for each compound. The 
molecular Weights of this group varied from 416 to 614 
depending on the substitutions at positions 2, 3 and 4 of the 
basic structure. The basic structure of this group Was syn 
thesized using synthetic methods B and C described beloW 
(see structure for NF 158 and NF 161). Additional substi 
tutions at positions 2, 3 and 4 Were made using synthetic 
methods A, Fa, Fb and G as indicated in Table 1. 
Table 2 shoWs seven phosphonic acid agents With large 
urea bridges. TWo basic structural formulas With four ben 
zene rings are shoWn With the chemical substitutions at each 
position, formula and molecular Weights for each com 
pound. The molecular Weights of this chemical group varied 
from 698 to 855 depending on the substitutions at 2, 3, 4, 4‘ 
and X of the basic structures. The basic structures of this 
45 
55 
60 
65 
group Were synthesized using synthetic methods A, B, C and 
D indicated beloW. (See NF 067, 068, 069 and 681). NF 540 
and NF 544 required synthetic steps Ea and Ec instead of D. 
Table 3 shoWs four phosphonic acid agents With miscel 
laneous structures. Because of differences in the basic struc 
tures of this group, the entire structure is shoWn With the 
formula and molecular Weights. The molecular Weights of 
this group varied from 424 to 949. NF 166 Was synthesized 
using synthetic method A described beloW. NF 167 required 
synthetic method A, B and C, Whereas NF 050 and NF 542 
required synthetic method A, B, A, B and C. 
Schemes 1 and 2 as set forth beloW shoW general proce 
dures for preparation of the novel compounds of this inven 
tion. In Scheme 1, the phosphonic acid agents are prepared 
by initial reduction of a nitro benzene phosphonic acid to the 
amino derivative. This amino derivative is then reacted With 
a di-acid halide to yield the phosphonic acid substituted 
agent (e.g. compounds 4a, b). Such di-acid halides include 
phosgene, thiophosgene and a dicarboxylic acid halide sub 
stituted aryl group. 
In an alternative embodiment, the amino derivative is 
reacted With a nitro benzoyl halide in a buffered medium and 
at temperatures of from about 20 to about 40° C. The 
nitrobenzoyl halide is added in an organic solvent such as 
toluene. At the conclusion of the reaction, the aqueous layer 
and organic layer are separated and the aqueous layer is 
6,096,730 
9 
acidi?ed by the addition of a mineral acid from Which a 
precipitated intermediate product, nitrobenZamido 
benZenephosphonic acid, is recovered. 
This nitrobenZamido-benZenephosphonic acid is then 
hydrogenated in the presence of a hydrogenation catalyst 
comprising a precious metal such as palladium or platinum 
on carbon to hydrogenate the nitro group and form an 
aminobenZamido-benZenephosphonic acid. 
The aminobenZamido-benZenephosphonic acid is then 
dissolved in a buffered aqueous medium and treated With 
phosgene in an organic solvent to produce the ?nal agent 
precipitated product. These reactions are described more 
speci?cally under Procedures A, B and C. 
10 
10 
reacted With the appropriate alkyl phosphite to form com 
pounds 13, 16 and 18, respectively. These compounds Will 
contain the appropriate substituents as shoWn in Scheme 2. 
More speci?cally, the chloromethyl substituted benZene 
12 is reacted With an alkyl phosphite by heating at about 80° 
C. up to re?ux for 3 to 10 hours. The resulting 12 is then 
nitrated to 13. Compound 14 may then be produced from 
compound 13 by heating With concentrated hydrochloric 
acid and crystalliZing the product. 
In a further embodiment, the nitrophenoXy carbonylchlo 
ride 15 is reacted With an alkylphosphite in an exothermic 
reaction to produce a nitrophenoXycarbonyl-phosphonic 
acid dialkyl ester 16. This intermediate can be converted by 
Scheme 1 
General synthesis of the phosphonic acid substituted agents: 
0 
o 
H2O3P 1 1' H2O3P 1 
\ C1 \ \ l, 
I —NH2 + —NH2 —> I —N 
/ 4 / 4' / 4 FL I —g 
3 31 1 2 
1a, b 
l 
H2O3P 1 1 PO3H2 
\ /B\ / 
| —T T— | 
3/ H H \3 
2a, b 
Substitution Pattern 
1, 3 
1, 4 
1, 3 
1, 3 
1, 4 
1, 4 
Scheme 2 sets forth a general synthesis for producing the 
\ 
3 / 4 
3, 
3c-f 
0 
H2O3P 1 
\ 1 
| —N \ 
/ 4 | I N 
3 H / 4' 51 
3, 
5c-f 
Various arylalkyp, phenoxycarbonyp, and carbamoyp 65 reaction With sodium iodide in a solvent With an haloalkyl 
phosphonic acid analogues. In these reactions, the substi 
tuted benZene derivatives, compounds 11, 15 or 17 are 
silane by heating at about 30° to about 50° C. to produce 
compound 19. 
6,096,730 
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Alternatively, the nitrophenylisocyanate (compound 17) 
is reacted With a dialkylphosphite in an exothermic reaction 
to yield the phosphonic acid ester (compound 18). 
Thereafter, the phosphonic acid ester is reacted With triso 
dium iodide in a solvent and With an halotrialkylsilane by 
heating at about 30° to about 60° C. to produce compound 
19. Compound 16 can be converted to compound 19 by the 
same procedure. 
12 
B. 4-(4-AminobenZamido)-benZenephosphonic acid (5f) 
Compound 3f (8.05 g) Was dissolved in a mixture of 1 M 
Na2CO3 (15 ml), Water (55 ml) and methanol (30 ml) (pH 
8.0) and hydrogenated at room temperature at normal pres 
sure using 10% Pd/C (200 mg) as catalyst. After absorption 
of the theoretical amount of hydrogen (about 4 hr), the 
?ltrate of the reaction mixture Was concentrated to 70 ml and 
acidi?ed With 2 N HCl to pH 6.0. The monosodium salt of 
Scheme 2 
General synthesis of arylalkyl—, phenoxycarbonyl-carbamoyl-phosphonic acid agents 
11a R=H 12a R=H 13a R=H 14a R=H 
11b R = cH2c1 12b R = CH2PO(OCH3)2 13b R = CH2PO(OCH3)2 14b R = CH2PO3H2 
‘IT OCH / 3 
1 0 c1 1 o P\ 
/ P(OCH3)3 / OCH3 
O2N— —> O2N— O 
4 \ O 4 O /OH 
1 X P\ 
1541-0 1641-0 1) C1—Si(CH3)3 / ONa 
2) H o N OH OZN I , a 
2 4 \ O 
19a-c X = O 
H 0 20a, b x = NH 
1 N—C_O I ‘ll/‘m3  — 1 \ 
/ HOP(OCH3)2 / OCH3 
O2N— —>O2N— I 
4 \ 4 0 
17a, b 18a, b 
15-20 
a: 4-NO2 
b: 3-NO2 
c: 2-NO2 
SYNTHETIC METHODS FOR PHOSPHONIC 
ACID AGENTS 
A. 4-(4-NitrobenZamido)-benZenephosphonic acid (3f) 
4-AminobenZenephosphonic acid (1b) Was prepared as 
described by Doak D. O. and Freedman C D, J. Amer Chem. 
Soc, 74, 753 (1952). Compound lb (17.3 g, 0.1 mol) Was 
dissolved in 2 N NaOH (100 ml). To this solution (pH 8), a 
solution of 4-nitrobenZoylchloride (2b, 30 g, 0.15 mol) in 
toluene (100 ml) Was added dropWise at room temperature 
With vigorous stirring. Stirring Was continued until no more 
1b Was detectable by TLC. Soon after the beginning of the 
addition of 4-nitrobenZoylchloride, 3f began to precipitate. 
NaOH (2 N) Was added to the reaction mixture at a rate that 
kept 3f in solution. At the end of the reaction, the aqueous 
layer Was pH 11. The toluene layer Was separated. The 
aqueous layer Was acidi?ed to pH 1.0 by addition of 
concentrated hydrochloric acid and stirred for 30 min. The 
precipitate Was ?ltrated and crystalliZed from methanol. 
Yield 25.3 g (78%). Melting point: 257—260° C. 
In a similar Way a series of aminoaryl- or aminoalkyl 
phosphonic acids Was benZoylated using nitrobenZene-mono 
or di-carbonylchlorides. 
55 
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compound 5f precipitated. It Was Washed With Water and 
dried at about 40° C. C13H13N2O4P (292.4); 
C13H12N2O4PNa (314.4) monosodium salt of compound 5f. 
In a similar Way all aromatic nitro compounds used as 
intermediates Were hydrogenated to the corresponding aro 
matic amino compounds. 
C. 4,4‘-[Carbonylbis(imino-4,1-phenylencarbonylimino)] 
bis-benZenephosphonic acid 
Compound 5f (5.85 g, 20) Was dissolved in Water (50 ml) 
and 5 M NaOH (4.0 ml). To this solution, a 20% solution (2 
M, 50 ml, 100 nmol) of phosgene in toluene Was added 
dropWise (4 hr) under vigorous stirring. During the Whole 
reaction time, the pH of the reaction mixture Was maintained 
at pH 5.0 by automatic addition of 5 M NaOH. A suspension 
Was formed during the addition of phosgene. The toluene 
layer Was separated. The aqueous suspension Was acidi?ed 
With 2 N HCl to pH 1 and stirred for 30 min. The precipitate 
Was ?ltered by suction, stirred three times With Water (20 ml, 
30 min) and dried. 
Yield: 3.6 g (61%) 
In a similar Way amino derivatives Were reacted With a 
di-acid halide to yield the phosphonic acid substituted agent. 
6,096,730 
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A thiophosgene or a dicarboxylic acid halide Was used to 
synthesize the corresponding agent. 
D. Tetrasodium salt of compound 6f 
Compound 3f (0.61 g 1.0 mol) Was suspended in Water 
(10 ml). The suspension Was titrated very slowly With 0.1 N 
NaOH to pH 9.0. The resulting clear solution Was evapo 
rated i. vacuum to dryness. 
TLC (Acetonitrile, NH3 conc., Water 6+2+2); compound 
6f Rf 0.63; compound 5f Rf 0.75; compound 3f Rf 0.79; 
4-NitrobenZoic acid Rf 0.75; HPLC purity of compound 
6f>96% determined by the method described by Kassack 
and Nickel (1996). 
E. 4-Nitro-1,3-xylene-ot,ot-diphosphonic acid (14b) 
a) 1,3-Bis-(chloromethyl)benZene (11b, 25 g, 0.1 mol) 
and triethyl phosphite (36.5 g, 0.22 mol) Were heated under 
re?ux for 10 hr. 
b) The reaction mixture (12b, yelloW oil) Was cooled to 
room temperature and added dropWise to a mixture of cone. 
nitric acid (30 ml, 0.4 mol) and cone. sulfuric acid (30 ml) 
at about 0—5° C. After 2 hr, the reaction mixture Was poured 
in ice Water (500 ml) and extracted With toluene. The toluene 
extracts Were Washed With Water and evaporated, yielding a 
yelloW oil (13b). 
c) Compound 13b Was heated With conc. hydrochloric 
acid under re?ux for 20 hr. The reaction mixture Was 
evaporated. The residue Was crystalliZed from Water yield 
ing yelloW crystals of compound 14b (mp 1720 C., 15.8 g, 
yield=50%). 
In a similar Way using steps a) and c) (4-nitrophenyl) 
methane phosphonic acid (14a) Was synthesiZed starting 
from 4-nitro-(x-chlorotoluene. 
F. (3-Nitrophenyl)carbamoyl phosphonic acid monosodium 
salt (20b) 
a) 3-Nitrophenylisocyanate ((17b) 0.82 g, 5 mmol) and 
dimethyl phosphite (0.55 g, 5 mmol) Were mixed. Addition 
of tWo drops of triethylamine led to a spontaneous exother 
mic reaction. The reaction mixture Was crystalliZed from 
methanol/ether yielding yelloW crystals (0.44 g, 32%), mp 
1070 C. (3-nitrophenylcarbamoyl phosphonic acid 
dimethylester, 18b). 
b) Compound 18b (5 mmol) and sodium iodide (10 mmol) 
Were dissolved in acetonitrile (30 ml). Chlorotrimethylsilane 
(15 mmol) Was added dropWise. The mixture Was heated to 
about 40° C. for 30 min, cooled and ?ltrated. The ?ltrate Was 
concentrated to a volume of 10 ml. Water (10 ml) Was added 
and the pH of the solution Was adjusted to pH 3 by addition 
of 0.1 N NaOH. The solution Was extracted three times With 
ether (15 ml). The aqueous phase Was freeZe-dried, yielding 
an amorphous poWder (20b). 
G. 4-Nitrophenoxycarbonylphosphonic acid dimethylester 
(16a) 
Trimethyl phosphite (4 ml, 30 mmol) Was added dropWise 
under stirring and cooling to 4-nitrophenoxycarbonyl chlo 
ride (15a, 6.4 g, 32 mmol) (exothermic reaction). The 
reaction mixture Was crystalliZed from ether/pentane yield 
ing yelloW crystals (16a, 6.8 g, 77%), mp 105° C. 
In a similar Way the 2-nitro- (16c) and 3-nitro- (16b) 
analogues Were synthesiZed. (See also Doak G O and 
Freedman C D]. Amer. Chem. Soc., 74: 753, 1952. Kassack 
M and Nickel P. J. Chromatogr. B, 686, 275—284, 1996, 
incorporated herein by reference in their entirety). 
The basic structure of the molecules synthesiZed Were 
similar to suramin. HoWever, the trisulfonic acid derivatives 
Were replaced With phosphonic acid groups (PO3HNa) or 
(—O—CO—PO3HNa) at the 2 (2‘), 3 (3‘) or 4 (4‘) positions. 
These alterations resulted in loWer molecular Weights 
(414—950) compared to the molecular Weight of suramin 
(1429) and other trisulfonic acid analogues (1162—1541). 
Both large urea and small urea phosphonic agents Were 
synthesiZed. The chemical and pharmacological properties 
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are very different from those described for other suramin 
analogues. The metabolic clearance rates of the phosphonic 
acid agents appear to be much faster (hours versus 45—55 
days for suramin). 
EXAMPLE 1 
Pharmacological Activities: Antiangiogenic Activity in the 
Chick Chorioallantoic Membrane Assay In Vivo and the 
Human Microvascular Endothelial Cells In Vitro 
The purpose of this experiment Was to test the ability of 
the phosphonic acid agents described above to inhibit angio 
genesis. The ID50, the dose that produces 50% inhibition of 
angiogenesis, Was determined for suramin and each of the 
phosphonic acid agents by measuring the ability of various 
doses to inhibit angiogenesis in vivo in the chick egg 
chorioallantoic membrane (CAM) assay as described by 
Gagliardi et al. 1992. Some of the phosphonic acid agents 
shoWed ID50 values signi?cantly loWer than suramin. TWo 
phosphonic acid agents, NE 069 and NE 681, shoWed the 
loWest ID50 values (4—8 times more active than suramin). 
Six other phosphonic acid agents shoWed antiangiogenic 
activity that Was 2 to 4 times greater than suramin (NE 050, 
NE 067, NE 161, NE 167 and NE 428). Other phosphonic 
acid agents Were equipotent to suramin. These data clearly 
indicate the discovery of a group of unique phosphonic acid 
agents Which shoW antiangiogenic activity that is up to 8 
fold greater than suramin in the CAM assay. 
It Was also found that the compounds described above, in 
general, shoWed a closely related antiangiogenic activity on 
the groWth of human dermal Microvascular endothelial cells 
stimulated by basic ?broblast groWth factor (bFGF) in vitro. 
The IC50 values for those phosphonic acid agents Were 
22—80 pM compared to 438 pM for suramin. This indicates 
that these phosphonic acid agents are 5—40 times more 
potent inhibitors of endothelial cell groWth than suramin in 
vitro. 
EXAMPLE 2 
Differences in the Effect of Suramin and the Phosphonic 
Acid Agents on Angiogenesis in the 6-Day Old and 11-Day 
Old CAM Assay 
According to Ausprunk et al. (1974), capillary angiogen 
esis in the CAM is completed by day 11. Measurements of 
intercapillary distances are also consistent With the cessation 
of capillary groWth after day 10. Flamme et al. (1991) 
shoWed that CAM ?uid contains angiogenic groWth factors, 
that the mitogenic activity of these groWth factors Was 
temporally related to the vascular groWth in the CAM, and 
that by day 10, there Was a sharp decrease in groWth factor 
activity in the CAM ?uid Which preceded the termination of 
capillary groWth by one day. Based on these observations, 
the effect of suramin and some phosphonic acid agents on 
the established vessels of the CAM membrane after cessa 
tion of vascular groWth Was determined. The implants Were 
prepared as previously described by Gagliardi et al. (1992), 
implanted on day 11 and read on day 13. 
The results of this study shoWed that the phosphonic acid 
agents (NE 067, NE 069, NE 681) Were very potent inhibi 
tors of angiogenesis in the 6-day CAM and exhibited no 
signi?cant inhibitory activity in the 11 day CAM (see Table 
4). Suramin shoWed antiangiogenic activity in both the 
6-day and 11-day CAMs. 
This is a very important ?nding and suggests that the 
phosphonic acid agents are very potent inhibitors of angio 
genesis during the phase of rapidly groWing vessels in the 
CAM (6-day) but do not affect the established vasculature 
(11-day CAM). On the other hand, suramin clearly affected 
both the groWing and established vascular cells. These 
results indicate that the mechanisms of action of suramin 
and the phosphonic acid agents on angiogenesis are differ 
ent. Additional experiments compare the mechanisms of 
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actions of the phosphonic acid agents on anglogenesis in 
vivo. 
TABLE 4 
Comparison of the inhibition of angiogenesis by 70 nmol of 
suramin or a equimolar amount of a phosphonic acid agents in the 
6-day and 11-day chick egg chorioallantoic (CAM assay. 
Chemical 6-day CAM 11-day CAM 
Analogues Structure % Inhibition % Inhibition 
suramin 64 50 
NF 068 phosphonic 0 0 
NF 067 phosphonic 63 0 
NF 069 phosphonic 68 0 
NF 681 phosphonic 100 0 
EXAMPLE 3 
Differences in the Inhibitory Effects of Suramin and the 
Phosphonic Acid Agents on bFGF-Stimulated and Non 
Stimulated Endothelial Cells 
Suramin is a highly charged molecule With six sulfonate 
groups that are ioniZed at physiologic pH. This results in 
signi?cant nonspeci?c binding to polypeptide groWth fac 
tors (Coffey et al., 1987). HoWever, suramin also exhibits 
speci?city by binding to speci?c sites on a groWth factor, 
similar to heparin binding to bFGF (Middaugh et al., 1992). 
While these studies shoWed that suramin is able to disrupt 
the binding of groWth factors to their receptors in intact 
cells, it also has diverse effects on other key enzymes 
involved in signal transduction and mitogenesis that prob 
ably contribute to its antiproliferative and antimetastatic 
activities. 
The data indicates that bFGF induced a dose-related 
increase in total protein and total DNA in human dermal 
microvascular and porcine pulmonary artery endothelial 
cells. The presence of suramin (210 pM) inhibited the 
stimulatory effect of bFGF, as has also been reported by 
Takano et al. (1994) and Braddock et al. (1994) for bovine 
aorta and bovine adrenal microvascular endothelial cells. In 
the presence of much loWer concentrations (25 pM), the 
phosphonic agents, NF 050, NF 067, NF 069, NF 681, NF 
161, NF 167 and NF 428, not only inhibited the stimulation 
of endothelial cell groWth by bFGF but signi?cantly reduced 
total protein content far beloW the unstimulated control 
endothelial cells. These exciting results shoW that the agents 
are much more potent inhibitors of endothelial cell groWth 
than suramin and that mechanisms other than blocking 
groWth factor binding to endothelial cells play a very 
important role in their antiangiogenic activity. 
The results With suramin are similar to those reported in 
the literature (Takano et al., 1994 and Braddock et al., 1994) 
that suramin inhibited I125 bFGF binding in a dose-related 
manner. HoWever, the phosphonic agents in the same molar 
concentrations used for suramin did not affect either the total 
or the speci?c binding of the iodinated groWth factor to the 
endothelial cells. The percentage of inhibition of I125 bFGF 
binding to loW and high af?nity binding sites of human 
microvascular endothelial cells Was 96% at 70 pM of 
suramin, decreasing to 9% at 25 pM of suramin. HoWever, 
for the same concentrations of the phosphonic acid agents, 
the inhibition of groWth factor binding Was alWays less than 
5% in relation to the control. These data clearly shoW that We 
have identi?ed a chemical group that are very potent as 
antiangiogenic agents and express their activity through 
different mechanisms than those Widely accepted for 
suramin. 
As described above, the phosphonic acid agents are very 
inhibitory in the actively groWing vessels of the 6-day CAM 
but shoWed almost no activity on the established vessels of 
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the 11-day CAM (see Table 2). When compared With the 
MTT assay con?uent and loW density cuphores in log phase 
groWth, the phosphonic acid agents are 10-fold more inhibi 
tory for groWing cultures than for con?uent human 
microvascular endothelial cell cultures. 
This in vitro ?nding corroborates our data With the CAM 
assay in different phases of groWth, suggesting that this neW 
class of phosphonic acid agents target groWing blood ves 
sels. 
EXAMPLE 4 
Differences in the GroWth Inhibitory Effects of Suramin and 
the Phosphonic Acid Agents in Human Microvascular 
Endothelial Cells and Established Cancer Cell Lines in 
Culture 
We have investigated the activity of the phosphonic acid 
agents on some tumor cell lines proliferation in vitro and 
compared this activity With the antiangiogenic activity of 
these compounds in the CAM assay and their inhibitory 
activity in human microvascular endothelial cell groWth. 
The MTT assay (Carmichael et al., 1987) Was used to 
examine the effects of suramin and selected phosphonic acid 
agents on cell proliferation. Suramin and the phosphonic 
acid agents inhibited cell proliferation in a dose-related 
manner. Analysis of the inhibitory action of the phosphonic 
acid agents in adrenal cortex carcinoma (SW13), human 
pancreatic adenocarcinoma (CFPAK- 1), human prostate car 
cinomas (LNCap and PC3) shoWed IC50 equipotent or 
values less than suramin. In other cell lines, such as human 
breast carcinomas (MCF7 and T47D), human ?brosarcoma 
(HT1080), human colon adenocarcinoma (CaCo2), human 
glioblastoma (U87), kidney carcinoma (A498) and lung 
carcinoma (A427), the phosphonic acid agents shoWed IC50 
values higher than suramin. 
The phosphonic acid agents, NF 067 (Which is 20 times 
more potent than suramin in inhibiting microvascular endot 
helial cell groWth), expressed very loW antiproliferative 
activity against different cancer cell lines in vitro. Our data 
and the reports in the literature strengthen our important 
?nding that some of the phosphonic acid agents are more 
potent inhibitors of angiogenesis in the CAM assay and to 
human microvascular endothelial cell groWth than suramin. 
This effect is not observed With some cancer cell lines. This 
suggests that there is speci?city for endothelial cells in the 
inhibitory effect of the phosphonic acid agents not observed 
With suramin and the other trisulfonic acid analogues. 
EXAMPLE 5 
The Toxicity of Suramin and the Phosphonic Acid Agents In 
Vivo in Mice 
A limitation on the clinical use of suramin is the narroW 
margin betWeen the dose required to achieve anti-tumor 
activity and that leading to the onset of prohibitive toxic side 
effects. Suramin toxicity has been revieWed by LaRocca et 
al. (1990). It is clear that compounds With similar antitumor 
activity to suramin but With substantially loWer toxicity 
Would be of considerable potential therapeutic value as an 
antitumorigenic or antiangiogenic agent. Toxicity studies 
Were performed With suramin, three sulfonic analogues 
more potent (2 times) than suramin in relation to inhibition 
of angiogenesis and endothelial cell groWth and four phos 
phonic agents (10 to 40 times more potent). Mice Were 
injected intraperitoneally With 0—150 pM/kg body Weight of 
the compounds to be tested, every other day for a total of ?ve 
injections. The animals Were carefully observed daily and 
Weighed every third day for 28 days after the last injection. 
After the 28-day observation period, the animals Were 
euthanized, blood Was collected through cardiac puncture 
and the folloWing tissues Were subjected to histological 
investigation: heart, lungs, liver, spleen, adrenal gland, 
kidney, sciatic nerve, soleus muscle and brain. 
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Animals treated With suramin at the highest dose (150 
pM/kg body Weight) died before completion of the ?ve 
injections. We observed poor coat condition, Weight loss, 
eye irritation and lacrimation by the end of the ?ve injections 
in animals treated With suramin. The poor coat condition and 
reduction of 10—15% in body Weight occurred at 150, 75 and 
35 pM/kg body Weight during the injection period. The coats 
and eye irritation became better but not normal and the body 
Weight stabilized but did not return to normal over the 
subsequent 28 days of observation. A similar response Was 
seen in tWo of the three sulfonic acid analogues that Were 
tested. On the other hand, no mice treated With the four 
phosphonic acid agents died during the acute injection 
phase. Furthermore, their body Weight did not decrease but 
they continued to gain Weight at the same rate as the control 
animals at all levels of treatment. The body coat Was normal 
and no eye irritation Was noted in all animals treated With 
phosphonic acid agents. 
Histological analysis of the tissues from animals treated 
With suramin shoWed a dose-related frequency of lipoid 
degeneration of the Zona reticularis of the adrenal gland and 
vacuolar changes in the proximal convoluted tubules of the 
renal tubular epithelium. The animals treated With equimolar 
doses of the phosphonic analogues shoWed no signi?cant 
changes in any important pathologic microscopic ?ndings in 
those tissue samples. 
These studies clearly indicate that the phosphonic acid 
agents shoW signi?cantly loWer toxicity than suramin and its 
trisulfonic acid analogs. 
EXAMPLE 6 
Structure-Activity Relationship for the Antiangiogenic 
Activity of the Phosphonic Acid Agents GroWing Vessels in 
the Chick Chorioallantoic Membrane Assay 
The phosphonic acid agents are extremely potent antian 
giogenic compounds With molecular Weights that are about 
half that of suramin. The phosphonic acid agents are up to 
30 times more active than suramin in the CAM assay. 
Furthermore, the nonspeci?c binding of these compounds to 
serum proteins is loWer than suramin and probably, as a 
consequence, a higher proportion is available in the free 
form to the cells and the half life is shorter. The siZe of the 
molecule also appeared important. Ten of the phosphonic 
acid agents have molecular Weights of less than 600 and 
contained small central urea bridges (see Table 1), shoWed 
less antiangiogenic activity than the seven phosphonic acid 
agents Which have big central urea bridges and higher 
molecular Weights (650—900) (see Table 2). Athird group of 
four phosphonic acid agents With miscellaneous structures is 
shoWn in Table 3. 
There is considerable variation in antiangiogenic activity 
in compounds of similar structure. For example, NF 068, 
Which is structurally very similar to NF 067, NF 069 and NF 
681 (all are phosphonic acid agents With the same molecular 
Weight), shoWed a substantial difference in the antiangio 
genic activity (0% inhibition) in comparison With the same 
concentration of NF 069 and NF 681 (90% inhibition). This 
suggests that slight steric modi?cations in the molecule can 
induce dramatic changes in the potency of inhibition of 
angiogenesis, opening neW avenues for antiangiogenic drugs 
design. 
EXAMPLE 7 
The Structure Activity Relationship for Inhibition of bFGF 
Induced Cell GroWth in Human Microvascular Endothelial 
Cells 
Dose response curves Were determined for the most active 
agents in human microvascular endothelial cell cultures 
treated With various concentrations in the presence or 
absence of bFGF. Inhibition of cell groWth Was evaluated by 
measuring total protein and total DNA and the IC50 Was 
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estimated for each dose response curve. The most potent 
compounds in relation to the inhibition of bFGF-induced 
endothelial cell groWth Were the phosphonic acid agents. 
Our results shoW a close correlation betWeen the inhibi 
tion of angiogenesis in vivo and the inhibition of endothelial 
cell stimulated groWth in culture for the selected agents. 
Among the ?ve most active agents in vitro, four Were 
phosphonic acid agents, the same compounds Which Were 
the most antiangiogenic in the CAM assay. These results 
suggest that the inhibition of angiogenesis in vivo in the 
CAM assay may involve a speci?c suppression of endothe 
lial cell groWth. Thus, We have identi?ed a speci?c group of 
phosphonic acid agents With signi?cantly loWer molecular 
Weight, less charged and much higher antiangiogenic activ 
ity than suramin and its sulfonic acid analogs. 
The ?nding that a unique chemical group of the phos 
phonic acid agents, are much more potent as antiangiogenic 
compounds, less toxic and With shorter half-lifes than 
suramin, suggest that the phosphonic acid agents are of 
clinical signi?cance and Widen the therapeutic WindoW for 
treatment of angiogenic dependent diseases. 
EXAMPLE 8 
Differences in the Inhibitory Effects of Suramin and the 
Phosphonic Acid Agents to bFGF-Stimulated and Non 
Stimulated Endothelial Cells 
Suramin is a highly charged molecule With six sulfonate 
groups that are ioniZed at physiologic pH. This results in 
signi?cant nonspeci?c binding to polypeptide groWth fac 
tors (Coffey et al., 1987). HoWever, suramin also exhibits a 
degree of speci?city by binding to speci?c sites on a groWth 
factor, similar to heparin binding to bFGF (Middaugh et al., 
1992). While these studies shoWed that suramin is able to 
disrupt the binding of groWth factors to their receptors in 
intact cells, it has diverse effects on other key enZymes 
involved in signal transduction and mitogenesis that prob 
ably contribute to its antiproliferative and antimetastatic 
activities. Our data shoWed that bFGF induced a dose 
related increase in total protein and total DNA in human 
dermal microvascular and porcine pulmonary artery endot 
helial cells. 
The presence of suramin (210 pM) inhibited the groWth 
factor stimulatory effect, as has also been reported by 
Takano et al. (1992) and Braddock et al. (1994) for bovine 
aorta and bovine adrenal microvascular endothelial cells. In 
the presence of much loWer concentrations (25 pM), the 
phosphonic agents, NF 067, NF 069 and NF 681, not only 
inhibited the stimulation of endothelial cell groWth by bFGF 
but signi?cantly reduced total protein content far beloW the 
unstimulated control endothelial cells. 
These results shoW that the phosphonic acid agents are 
much more potent than suramin in inhibiting angiogenesis 
and that mechanisms other than blocking groWth factor 
binding to endothelial cells play a very important role in 
their antiangiogenic activity. Results With suramin are simi 
lar to those reported in the literature (Takano et al., 1992 and 
Braddock et al., 1994) that suramin inhibited bFGF binding 
in a dose-related manner; but the phosphonic analogues in 
the same molar concentrations used for suramin did not 
affect either the total or the speci?c binding of the iodinated 
groWth factor to the endothelial cells. 
The percentage of inhibition of I125 bFGF binding to loW 
and high af?nity binding sites of human microvascular 
endothelial cells Was 96% at 70 pM of suramin, decreasing 
to 9% at 25 pM of suramin. HoWever, for the same concen 
trations of phosphonic acid agents, the inhibition of groWth 
factor binding Was alWays less than 5% in relation to the 
control. These data clearly shoW that there is identi?ed a 
chemical group of phosphonic acid agents that are very 
potent as antiangiogenic agents that express their activity 
through different mechanisms than those Widely accepted 
for suramin. 
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The phosphonic acid agents are very inhibitory in the 
actively growing vessels of the 6-day CAM but showed 
almost no activity on the established vessels of the 11-day 
CAM. When compared With the MTT assay con?uent and 
loW density cultures in log phase groWth, the phosphonic 
acid agents are 10-fold more inhibitory for groWing cultures 
than for con?uent human microvascular endothelial cell 
cultures. This in vitro ?nding corroborates our data With the 
CAM assay in different phases of groWth, suggesting that 
this neW class of suramin analogues target groWing blood 
vessels and does not effect established blood vessels. 
EXAMPLE 9 
Differences in the GroWth Inhibitory Effects of Suramin and 
the Phosphonic Acid Analogues in Human Microvascular 
Endothelial Cells and Established Cancer Cell Lines in 
Culture 
We have compared the activity of suramin and the phos 
phonic acid agents on some tumor cell lines proliferation in 
vitro and compared this activity With the antiangiogenic 
activity of these compounds in the CAM assay and their 
inhibitory activity in human microvascular endothelial cell 
groWth. The MTT assay (Carmichael et al., 1987) Was used 
to examine the effects of suramin and selected phosphonic 
acid analogues on cell proliferation. Suramin and the phos 
phonic acid agents inhibited cell proliferation in a dose 
related manner. Analysis of the inhibitory action of suramin 
and the phosphonic acid agents in adrenal cortex carcinoma 
(SW13), human pancreatic adenocarcinoma (CFPAK-1), 
human prostate carcinomas (LNCap and PC3) shoWed IC50 
value equipotent or less than suramin. In other cell lines, 
such as human breast carcinomas (MCF7 and T47D), human 
?brosarcoma (HT1080), human colon adenocarcinoma 
(CaCo2), human glioblastoma (U87), kidney carcinoma 
(A498) and lung carcinoma (A427), the phosphonic acid 
agents shoWed equipotent or loWer inhibitory activity in 
comparison to suramin. 
Our data strengthened our important ?nding that the 
phosphonic acid agents are much more potent inhibitors of 
angiogenesis in the CAM assay and to human microvascular 
endothelial cell groWth than suramin. This effect is not 
observed With some cancer cell lines. This suggests that 
there is speci?city for endothelial cells in the antiangiogenic 
effect of the phosphonic acid agents. 
EXAMPLE 10 
Comparative Toxicity of Suramin, Trisulfonic Analogues 
and the Phosphonic Acid Agents In Vivo in Mice 
A limitation on the clinical use of suramin is the narroW 
margin betWeen the dose required to achieve anti-tumor 
activity and that leading to the onset of prohibitive toxic side 
effects. Suramin toxicity has been revieWed by LaRocca et 
al. (1990). It is clear from studies so far that compounds With 
equipotent or greater antitumor activity but With substan 
tially loWer toxicity are of considerable potential therapeutic 
value as an antitumorigenic or antiangiogenic agent. Pre 
liminary toxicity studies Were performed With suramin, three 
sulfonic analogues more potent (2 times) than suramin in 
relation to inhibition of angiogenesis and endothelial cell 
groWth and the four most active phosphonic analogues (up 
to 30 times). Mice Were injected intraperitoneally With 
suramin or equimolar doses of the sulfonated analogues or 
the phosphonic analogues or the phosphonic acid agents 
(1—150 pM/Kg body Weight) every other day for a total of 
?ve injections. The animals Were carefully observed daily 
and Weighed every third day for 28 days after the last 
injection. After the 28-day observation period, the animals 
Were euthaniZed, blood Was collected through cardiac punc 
ture and the folloWing tissues Were kept for histological 
investigation: heart, lungs, liver, spleen, adrenal gland, 
kidney, sciatic nerve, soleus muscle and brain. 
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Animals treated With suramin at the highest dose (150 
pM/Kg body Weight) died before completion of the ?ve 
injections. Poor coat condition, Weight loss, eye irritation 
and lacrimation Was observed by the end of the ?ve injec 
tions in animals treated With suramin. The poor coat con 
dition and reduction of 10—15% in body Weight occurred at 
150, 75 and 35 pM/Kg body Weight during the injection 
period. The coat condition and eye irritation became better 
but not normal and the body Weight stabiliZed but did not 
return to normal over the subsequent 28 days of observation. 
On the other hand, mice treated With the phosphonic acid 
agents did not die during the acute injection phase. 
Furthermore, their body Weight did not decrease but they 
continued to gain Weight at the same rate as the control 
animals at all levels of treatment. The body coat Was normal 
and no eye irritation Was noted. 
Histological analysis of the tissues from animals treated 
With suramin shoWed a dose-related frequency of lipoid 
degeneration of the Zona reticularis of the adrenal gland and 
vacuolar changes in the proximal convoluted tubules of the 
renal tubular epithelium. The animals treated With equimolar 
doses of the phosphonic acid agents shoWed no signi?cant 
changes in any important pathologic microscopic ?ndings in 
those tissue samples. These preliminary studies clearly indi 
cate that the phosphonic acid agents shoW a greater than 
10-fold increase in antiangiogenic activity and signi?cantly 
loWer toxicity. 
EXAMPLE 11 
Structure of Phosphonic Acid Agents 
The phosphonic acid agents studied Were selected based 
on the criteria of drug potency in relation to inhibition of 
angiogenesis in the CAM and inhibition of microvascular 
endothelial cell groWth in vitro, availability, chemical purity 
and sampling of each different chemical structure subgroup. 
TWenty-tWo phosphonic acid agents, including NF 067, NF 
068 NF 069, NF 681, and NF 162, synthesiZed by our 
laboratory, are used in various concentrations. In the CAM 
assay, the ID50 for suramin Was 75 nmol and the ID50 for 
the phosphonic acid agents, NF 069, NF 681 and NF 067, 
Was respectively, 9, 2 and 32 nmol. The estimated IC50 for 
suramin in the bFGF-stimulated human microvascular 
endothelial cells Was 437 pM and for NF 069, NF 681 and 
NF 067 Were respectively, 75, 1.5 and 19.4 pM, re?ecting 
activity that is up to 200 times more potent than suramin. NF 
068 is a closely related compound chemically Which does 
not shoW any antiangiogenic activity. The structures of these 
phosphonic acid agents and suramin are shoWn in Tables 
1—3. 
The inventors have identi?ed a clear correlation betWeen 
the chemical structure and antiangiogenic activity. The phos 
phonic acid agents are far more potent inhibitors of angio 
genesis and bFGF-stimulated endothelial cell groWth than 
any suramin. Furthermore, the phosphonic acid analogues 
With large central urea bridges are in general more active 
than the group With small central bridges or other con?gu 
rations. 
EXAMPLE 12 
Effects of the Phosphonic Acid Agents and Suramin on DNA 
Synthesis and Human Microvascular Endothelial Cell 
GroWth 
3H-Thymidine incorporation is used to determine the 
effect of the phosphonic acid agents and suramin on DNA 
synthesis in HMEC-1 and HMVEC-d cells. Logarithmically 
groWing HMEC-1 or HMVEC-d cells are seeded at 2><104 
cells/Well in six Well plates (Falcon) containing 2 ml of 
MCDB-131 medium supplemented With 5% fetal bovine 
serum (FBS) (Hyclone). Various amounts of suramin (0—500 
pM) and equimolar concentrations of the phosphonic acid 
agents are added to different Wells, and the plates incubated 
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for 24 hr. 3H-Thymidine (ICN Radiochemicals) is added and 
incorporation allowed to proceed for an additional 30 min. 
After removal of medium, the cell layer is Washed tWice 
With 1 ml of cold Hanks balanced salt solution and the cells 
are dislodged by trypsiniZation. The cells are collected in 
microcentrifuge tubes and Washed tWice With 1 ml of cold 
phosphate-buffered saline, and then 1 ml of cold 10% 
trichloroacetic acid are added. Acid precipitable radioactiv 
ity are collected on a glass ?ber ?lter (Whatman Grade 
GF/C) and the radioactivity is determined in a liquid scin 
tillation spectrometer (Packard). 
The effect of various concentrations of suramin and the 
phosphonic acid agents on cell groWth and ongoing DNA 
synthesis is measured. The inventors found that concentra 
tions of suramin up to 100 pig/ml did not have any signi?cant 
inhibitory effect on HMEC-1 and porcine pulmonary artery 
macrovascular endothelial cell groWth. As a matter of fact, 
a stimulatory effect on cell groWth With suramin at 50—100 
pig/ml Was detected. HoWever, at concentrations higher than 
250 pig/ml, there Was a signi?cant dose-related reduction in 
total protein and total DNA. The phosphonic acid agents 
alWays shoWed potent reduction in total protein and total 
DNA even at loWer concentrations, suggesting, once again, 
a different and speci?c mode of action on endothelial cells 
by the agents. 
EXAMPLE 13 
The Time Course for Inhibition of Protein Synthesis by the 
Phosphonic Acid Agents in Human Microvascular Endot 
helial Cells 
3H-Leucine incorporation is used to determine the effect 
of the phosphonic acid agents and suramin on protein 
synthesis in HMEC-1 and HMVEC-d cells. HMEC-1 or 
HMVEC-d cells are groWn to con?uence in ?asks (P100) 
and IC50 doses of the phosphonic analogues or suramin are 
added for time periods of 6 to 36 hr. For each time period, 
six replicate ?asks are set up. The volume of the medium 
MCDB-131 is 10 ml per ?ask. After incubation, the medium 
Was replaced With fresh MCDB-131 containing 0.37 MB ml 
of 3H-leucine and incubated for a further 90 min. TritonX 
100 (240 ml, 10%) Were then added to the contents of each 
?ask and agitated. Trichloroacetic acid (TCA) (4 ml, 20%) 
is added, the contents mixed and the ?asks left overnight at 
room temperature. After 24 hr, the ?ask contents Was 
suspended by shaking, transferred to tubes and centrifuged 
at 4300 g. The pellets Were resuspended in 10% TCA and 
recentrifuged and then resuspended in 3.0 ml of 0.1 M 
NaOH. Half of this volume Was transferred to scintillation 
vials in 10 ml of Emulsi?er Safe scintillation ?uid (Packard) 
While the remaining 1.5 ml Was used to assay DNA content 
(LaBarca and Paigen, 1980). The radioactive counts due to 
protein synthesiZed in the presence of 3H-leucine Was nor 
maliZed to counts/pg DNA. Protein synthesis by cells treated 
With the phosphonic acid agents are expressed relative to 
that of control cells as the percent of inhibition for each time 
of incubation. 
Comparison of 3H-leucine incorporation into cellular pro 
tein in the presence or absence of suramin and the phos 
phonic acid agents Was used as a measure of the inhibition 
of protein synthesis. There Was no change in the rate of 
protein synthesis until suramin and the cells have been 
incubated together for at least 24 hr. It Was shoWn that this 
is the time necessary for a reasonable amount of suramin to 
be taken up by HMEC-1 cells (Gagliardi et al., 1996). After 
this period of time, the rate steadily declines. The inhibition 
of protein synthesis by the phosphonic acid agents Was 
signi?cant after a short time of incubation because these 
compounds are smaller and less charged than suramin. 
EXAMPLE 14 
Determination of the Sensitive Phase of the Cell Cycle for 
the Inhibitory Effects of the Phosphonic Acid Agents and 
Suramin on Human Microvascular Endothelial Cells 
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Suramin has been shoWn to inhibit cell cycle progression 
at different phases in various cancer cell lines. There is no 
data available on the effect of the phosphonic acid agents 
and suramin on cell cycle in human microvascular endot 
helial cells. Jindal et al. (1990) ?rst described the inhibitory 
action of suramin on DNA synthesis and proposed that it Was 
due to a direct action on cellular DNA polymerases. Data 
from in vitro studies suggest that the optimal bene?t from 
suramin may require prolonged exposure time. It has been 
reported that prostate carcinoma cells, treated in vitro With 
suramin, are sloWly arrested in the G1 phase. Cell arrest in 
the G1 phase became evident only after 24 hr of exposure 
and suramin also induced a decrease in cells in the S phase 
(Qiao et al., 1994). Suramin inhibited proliferation of human 
cerebral meningioma cells and increased the percentage of 
cells in the S and G2/M phase of the cell cycle. As suramin 
simultaneously decreased the proliferation rate shoWn by 
direct cell counting and 3H-thymidine uptake, the effect in 
the G2/M phase cannot be attributed to increased prolifera 
tive activity. 
Consequently, suramin must lead to a prolongation of the 
S and G2/M phases or to an arrest during these cell cycle 
phases. HoWever, the data shoWed that the human microvas 
cular endothelial cells are much more sensitive to inhibition 
by both suramin and the phosphonic acid agents than the 
large vessel endothelium, suggesting a stronger promoting 
activity of bFGF on microvascular as opposed to macrovas 
cular endothelial cells, as described by Braddock et al. 
(1994). 
EXAMPLE 15 
Effects of the Phosphonic Acid Agents on the Transit Time 
of Endothelial Cells Through the Cell Cycle 
Experiments using ?oW cytometry are performed to deter 
mine the effects of the phosphonic acid agents at different 
doses and comparing them to the results With suramin. 
HMEC-1 and HMVEC-d synchroniZed cells are used to 
analyZe the effects of selected phosphonic acid agents on the 
distribution of cells in the various phases of the cell cycle 
using the propidium iodide method according to Vindelov et 
al. (1985). Brie?y, 104 cells are seeded With MCDB-131. 
After 24 hr, the medium is replaced With fresh medium 
containing the test compounds at 0—500 pM. After exposure 
times of 12, 24, 48 and 72 hr, the cells are collected by 
trypsiniZation, stained With propidium iodide and analyZed 
by ?oW cytometry for the percentage of cells in G0/G1, S, 
and G2/M phase. 
These studies compare the effects of the phosphonic acid 
agents on the percentage of cells in different phases of the 
cycle for human microvascular endothelial cells. These 
results enable us to understand if the same mechanisms are 
involved in the inhibition of endothelial cell groWth by 
phosphonic acid agents and suramin. 
EXAMPLE 16 
Determination of the Involvement of Cell Signaling Path 
Way Components, Protein Kinase C and p34CDC2 Kinase, 
on the Inhibition of Human Microvascular Endothelial Cell 
GroWth by the Phosphonic Acid Agents 
Many studies have unraveled the importance of cell 
signaling pathWays in the inhibitory action of certain com 
pounds. Protein kinase C (PKC) is involved in apoptosis 
induction by some compounds, and suramin has been shoWn 
to inhibit PKC. Suramin inhibits PKC type I—III activity in 
a concentration-dependent manner With an ID50=50 pM. 
The inhibition of cyclic AMP-dependent protein kinase 
activity Was much less sensitive to suramin With an IC50= 
656 pM (Mahoney et al., 1990). Similar inhibitory effects 
Were observed With M-kinase, the constitutively active cata 
lytic fragment of PKC, and autophosphorylation of PKC 
types I—III. 
6,096,730 
23 
PKC consists of a family of gene products in animal 
tissues composed of at least ten distinct proteins (alpha, beta, 
gamma, delta, epsilon, eta, theta, Zeta, iota and mu) that are 
important regulatory elements in signal transduction, cellu 
lar regulation and tumor promotion. It has been shoWn that 
endothelial cell proliferation in response to bFGF is depen 
dent upon activation of PKC (Kent et al., 1995) and that 
activation of PKC is both necessary and sufficient for 
attachment, spreading and migration of human endothelial 
cells (Yamamura et al., 1996). The distribution of PKC 
isotypes is cell speci?c. The discovery of these isotypes that 
have distinct physiologic functions provides an explanation 
for the plethora of cellular events that are mediated by PKC. 
Investigation of PKC isotypes in human umbilical vein 
macrovascular endothelial cell (HUVEC) With Northern and 
Western blot analyses demonstrated the presence of PKC 
alpha, delta, epsilon, eta, theta and Zeta (Haller et al., 1996). 
Endothelial cell stimulation by bFGF has been Well docu 
mented to increase cytosolic and perinuclear PKC alpha and 
epsilon immunoreactivity. These same PKC isotypes Were 
markedly doWn regulated after prolonged treatment With 
phorbol esters (Yamamura et al., 1996). 
The doWn regulation of PKC alpha and epsilon inhibited 
endothelial cell migration and proliferation. These ?ndings 
suggest that PKC alpha and epsilon are the isotypes involved 
With cytoskeleton events, endothelial cell migration and the 
proliferative response to bFGF. Because of the importance 
of PKC in regulating pleiotropic biological processes, it is of 
importance to identify the inhibition of PKC by the phos 
phonic analogues in endothelial cells. 
EXAMPLE 17 
Effects of the Phosphonic Acid Agents on PKC Activity, In 
Situ, in Human Microvascular Endothelial Cells in Culture 
HMEC-1 or HMVEC-d cultures are groWn to con?uence 
on gelatiniZed 96-well plates. After a 24-hr incubation With 
the MCDB-131 culture medium containing 5% FBS, cells 
are Washed With MCDB-131 only and then incubated With 
the experimental media. Several experiments are necessary 
to understand the role of the phosphonic acid agents on 
PKC. Con?uent cells are treated With bFGF (10 ng/ml) in 
the presence or absence of suramin (100, 200, 400 and 800 
pig/ml) or equimolar concentrations of the phosphonic acid 
agents for 5—10—30—60 and 120 minutes. Con?uent cultures 
are treated With the active phorbol esters, PMA and PDD 
(10—200 ng/ml), and the inactive analogue, 4-ot-PDD 
(Montesano and Orci, 1985) in the presence or absence of 
suramin or selected phosphonic acid analogues. A speci?c 
inhibitor for PKC, RO-318220, is also used in a similar 
manner as the control. After the indicated time points, the 
cells are Washed With cold PBS and PKC is assayed With 
(Ac-MBP(4-14)), Which acts as speci?c substrate of PKC 
(Koide et al., 1992). To each Well, 100 pl total volume of the 
folloWing are added: lysis buffer (?nal concentration: 0.137 
mM NaCl, 5.4 pM KCl, 0.3 pM Na3PO4, 0.4 pM K2HPO4, 
1 mg/ml glucose, 20 mM HEPES, 10 mM MgCl2, 50 pig/ml 
digitonin and 25 mM B-glycerophosphate, pH 7.2), 100 pM 
(gamma32P) ATP, 2.3 mM CaCl2, 2 pig/ml 
phosphatidylserine, and 100 pM Ac-MBP. After incubation, 
50 pl from each Well are spotted onto phosphocellulose 
disks, Washed With 1% concentrated H3PO4 in Water, and 
counted. Results are expressed as the percentage of inhibi 
tion in comparison to cultures treated With bFGF or active 
phorbol esters. 
The phosphonic acid agents shoW a strong inhibitory 
effect on PKC activity and this effect can be counter bal 
anced by the addition of active phorbol esters. A clear 
inhibition of PKCa, the isotype that seems to play the most 
important role in endothelial cells. 
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EXAMPLE 18 
PKC Isotypes Involved in Induction of Apoptosis in 
Microvascular Endothelial Cells 
Several experiments are necessary to understand Which 
isotypes of PKC respond to cell groWth and apoptosis. The 
expression of different PKC isotypes are determined in 
subcon?uent cultures, con?uent quiescent cultures, subcon 
?uent cultures treated With bFGF or VEGF, subcon?uent 
cultures treated With each of the phosphonic acid agents and 
subcon?uent cultures treated With bFGF or VEGF. Subcon 
?uent cultures are also treated With the active phorbol esters 
(10—200 ng/ml), PMA and PDD and the inactive analog, 4 
a-PDD (control) (Montesano and Orci, 1985). HMEC-1 and 
HMVEC-d cells are also treated With the phorbol esters in 
the presence or absence of the various phosphonic acid 
analogues. A speci?c inhibitor for PKC, RO-318220, are 
also used in a similar manner With and Without the phos 
phonic acid analogues (Tsopanoglou, 1994). 
The total RNA is extracted and the mRNA for the speci?c 
isotypes is determined by Northern blots as described by 
Mattila et at. (1994). The protein for each speci?c PKC 
isotype is separated and determined by Western blot analysis 
(Mattila et al., 1994). The measure of apoptosis is carried out 
in dishes treated in the same fashion as described above. 
Cells are analyZed for apoptosis as described. 
The conventional PKC isotypes (alpha, beta, gamma) are 
calcium and phospholipid dependent Whereas the novel 
isotypes (delta, epsilon, eta and theta) do not require calcium 
for activation. Zeta is both calcium and phorbol ester inde 
pendent. The isotypes have not been reported in any human 
microvascular endothelial cells. HoWever, for the rat mac 
rovascular and human macrovascular cells, only alpha and 
epsilon appear to be involved in groWth. The experiments 
hoW Which PKC isotypes are stimulated by phorbol esters or 
are inhibited by the phosphonic acid analogues. Amajor goal 
is to determine if these PKC isotypes an overcome their 
inhibition by phosphonic acid analogues When treated With 
phorbol esters. This Would suggest that PKC is a major 
pathWay for the induction of apoptosis in the human 
microvascular endothelial cells. 
EXAMPLE 19 
Effects of the Phosphonic Acid Agents on p34CDC2 Kinase 
Activity in Human Microvascular Endothelial Cells in Cul 
ture 
CDC2 kinase is the key enZyme controlling G2-M tran 
sition in human cells and its inactivation results in cell cycle 
interruption and G2 block (BojanoWski et al., 1994). In 
studies using DNA ?oW cytometry, suramin inhibited men 
ingioma cell proliferation in ?ve different tumor lines by 
arresting cells in G2-M and S phases of the cell cycle 
(Schrell et al., 1995). These effects Were found under 
serum-containing and serum-free culture conditions, and in 
the absence or presence of estradiol or insulin-like groWth 
factor-1. Prolonged exposure (48 hr) to suramin caused an 
accumulation of MCF-7 human breast cancer cells in the 
G2-M phase of the cell cycle (Foekens et al., 1993). Suramin 
has a direct inhibitory effect on puri?ed cdc2 kinase and also 
modulates the tyrosine phosphorylation of cdc2 kinase in 
extracts from human small cell lung cancer cells, suggesting 
that suramin might have a double inhibitory effect on cdc2 
kinase in vivo: one blocking the kinase activity and the 
second, protecting the tyrosine phosphorylation of the 
enZyme. CDC kinase Was found to be important in cell 
proliferation, and suramin Was reported to in?uence this 
kinase as Well. 
The effects of selected phosphonic acid agents on the 
p34cdc2-related kinase activity are carried out essentially as 
described by BojanoWski et al. (1994). 
Cytoplasmic and nuclear extractions: 100 million cells 
(HMVEC-1 or HMEC-d) are Washed tWice With cold PBS 
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and incubated in hypotonic phosphate buffer for 45 min on 
ice. The cells are then disrupted With a Dounce homogeniZer 
and nuclei separated from the cytoplasmic fraction by cen 
trifugation and extensive Washing With hypotonic buffer. 
The nuclei are incubated for 30 min in the presence of 350 
mM NaCl and the nonsoluble nuclear material removed by 
ultracentrifugation (20 min at 40000 rpm in TL 100 Beck 
man ultracentrifuge). The protein concentration are adjusted 
to 1.5 mg/ml, 20% of glycerol are added and the extracts 
stored at —20° C. 
p13-agarose precipitation: extracts (300 pg protein) or 
puri?ed p34cdc2 kinase (50 ng protein) are diluted in 400 pl 
of precipitation buffer in the presence and absence of 
suramin (0—20—120 pM) or the phosphonic acid agents in 
equimolar concentrations. After 10 min, 15 pl of p13 
agarose are added and samples incubated at 4° C. for 1—3 hr. 
The samples are subjected to a brief centrifugation, the 
supernatant eliminated and the precipitates are Washed four 
times in precipitation buffer With vortexing and transferred 
to a clean Eppendorf tube after the third Wash. The precipi 
tates are used immediately for kinase assays or Western blot. 
p34cdc2 kinase assay: 25 ng of puri?ed p34cdc2 kinase or 
p-13 agarose precipitates are incubated in 20 pl of kinase 
buffer, 32P-ATP and p34cdc2 kinase substrate, With or 
Without suramin and the phosphonic acid agents at 25° C. for 
20 min. Reactions are stopped by placing the samples on ice 
and spotting 5 pl of the reaction mixture onto P81 phospho 
cellulose ?lters (Whatman). Filters are Washed three times in 
50 mM phosphoric acid, dried and the radioactivity retained 
on the ?lters are determined by liquid scintillation 
(Beckman). 
Western blot: the precipitates are electrophoresed in 
12.5% 12x12 cm ready-made polyacrylamide gels (Daichi 
Co.) and the proteins transferred to Immobilon PVDF mem 
branes (Millipore). Nonspeci?c binding sites on the mem 
branes are saturated With 5% skim milk in PBS. The 
immobiliZed antigens are revealed using bitinylated second 
ary antibodies With biotinyl-tyramide/streptavidin reagent 
(Blast kit, Dupont, USA) to increase the sensitivity of the 
signal and NitrotetraZolium/NADH substrate (POD kit, 
WAKO, Japan) to visualiZe it. A Pharmacia LKB image 
master DTS chromoscan are used for band quanti?cation 
(BojanoWski et al., 1994). 
Suramin inhibits p34cdc2 kinase activity in a dose-related 
manner and the phosphonic acid agents are also potent 
p34cdc2 kinase inhibitors. Suramin has been reported to 
increase the global tyrosine speci?c phosphorylation of 
cellular proteins in vivo and the ?rst suramin-sensitive 
tyrosine phosphatase has recently been described (Ghosh 
and Miller, 1993). The Western blot shoWs different elec 
trophoretic mobility p34cdc2 kinase bands betWeen samples 
treated or not treated With suramin and the phosphonic acid 
agents, and the immunoblot With anti-phosphotyrosine anti 
body exhibits a difference in p34cdc2 kinase tyrosine phos 
phorylation. 
EXAMPLE 20 
Programmed Cell Death (Apoptosis) Induced by Phospho 
nic Acid Agents in Human Microvascular Endothelial Cells 
To measure the induction of apoptosis by the phosphonic 
acid agents, quiescent and exponentially groWing endothe 
lial cells are analyZed. After 24 hr of seeding (loW cell 
density) or after con?uence is reached (high cell density), 
the medium is changed With fresh medium containing vari 
ous amounts of the phosphonic acid agents. The experiments 
With con?uent cultures are carried out also in the presence 
or absence of bFGF (10 ng/ml). After various exposure times 
(6—36 hr), the cells are harvested and analyZed for the 
induction of apoptosis by four different methods: 
a) The cells are ?xed With 70% ethanol, spread onto 
microscope slides, stained With acridine orange and ana 
lyZed for nuclei (500 cells counted per data point). 
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b) The cells are ?xed in 4% buffered formalin, air dried 
onto lysine coated slides, quenched for endogenous peroxi 
dases With 2% hydrogen peroxide, treated With terminal 
deoxyribonucleotide triphosphatase, folloWed by anti 
dioxigenin-peroxidase, DAB substrate solution and ?nally, 
methyl green. Cells (100) are counted to determine the 
percentage of Apotag-positive cells per data point. 
c) To demonstrate DNA fragmentation (DNA laddering), 
harvested cells re treated With protease k and sodium dode 
cyl sulfate for 12 hr to degrade cellular protein. The DNA are 
extracted With phenol/chloroform/isoamyl alcohol, folloWed 
by ethanol precipitation. The air dried DNA pellet is 
re-suspended in TE buffer and run on a 1% agarose gel for 
2 hr at 120 volts. The gels are stained With ethidium bromide 
and photographed. 
d) To determine the time course of events more exactly 
and to discover Whether the cells enter apoptosis from the 
G0/G1 stage or S/M stages, a neW ?oW cytometry method 
established in our Flow Cytometry Core Facility based on 
the method of Reid et al. (1996) is used. The harvested cells 
are stained With Hoechst 33342 and merocyanine 540, 
analyZed by How cytometry and divided in ?ve groups: 
viable G0/G1, viable s/G2/M, early apoptotic G0/G1, early 
apoptotic S/G2/M, and fragmented DNA (late apoptotic) 
cells. 
The phosphonic acid agents induce programmed cell 
death in human microvascular endothelial cells that are 
actively proliferating and that the apoptosis process is trig 
gered by cell detachment. 
EXAMPLE 21 
Uptake and Intracellular Distribution of 3H-phosphonic 
Acid Analogues by Human Microvascular Endothelial Cells 
We have already shoWn that 3H-suramin is taken up by 
human microvascular endothelial cells in culture and that 
suramin is probably transported by the caveolae system. The 
suramin incorporation by HMEC-1 cells increased and 
reached a plateau around 24 hr of incubation, and more than 
50% of the suramin taken up by HMEC-1 cells Went to the 
nucleus. Our group is synthesiZing various tritiated phos 
phonic acid agents that are used for experiments in HMEC-1 
and HMVEC-d cells. Brie?y, tritiated suramin (13 pCi/100 
ml of MCDB-131 Without FBS) obtained from Moravek 
Biochemicals (Brea, Calif.) Was incubated at 37° C. in 5% 
COZ/air for different periods of time (2—72 hr). Triplicates 
Were carried out for each period of incubation. At the end of 
each incubation period, the cells Were processed through 
different Washings and ?nally to differential centrifugation. 
Different cell fractions Were transferred to separate scintil 
lation vials, solubiliZed in a liquid scintillation cocktail and 
counted in a 2000 CA TRICARB Liquid Scintillation 
Counter. 
The phosphonic acid analogues are taken up by HMEC-1 
and HMVEC-d cells much faster and in higher amounts than 
suramin because the phosphonic acid agents are smaller, less 
charged molecules than suramin and less bound to proteins. 
The demonstration that the phosphonic acid agents can reach 
signi?cant intracellular concentrations and its localiZation is 
very important for the understanding of the mechanism of 
action of these compounds. 
EXAMPLE 22 
Effects of Phosphonic Acid Agents on Programmed Cell 
Death in the Chick Chorioallantoic Membrane (CAM) 
The CAM assay has been reported as a suitable model for 
the demonstration of “in vivo” induced apoptosis (Brooks et 
at., 1994). We have shoWn that suramin and the phosphonic 
acid agents are potent inhibitors of angiogenesis in the 6-day 
CAM assay. To explore the possibility that suramin and/or 
the phosphonic acid agents induce apoptosis in vascular 
cells, 6-day old chick embryos are treated With suramin or 
6,096,730 
27 
the phosphonic acid agents (0—200 pM) and injected in the 
CAM ?uid (in the 6-day CAM, the angiogenic vessels grow 
rapidly embedded With CAM ?uid). After 24, 48 and 72 hr 
of treatment With the compounds or saline as control, the 
CAMs are resected for DNA isolation and analysis for 
oligonucleosomal fragmentation as previously described by 
Brooks et al., (1994). To identify those cells Within the CAM 
undergoing apoptosis in response to the treatment With the 
phosphonic acid agents, cryostat sections prepared from 
CAMs treated for 24—48 and 72 hr are examined for apop 
tosis by the Apo-Tag immunoreactivity kit and for endot 
helial cell speci?c staining. Co-localiZation of these markers 
in the same cells demonstrate that inhibition of angiogenesis 
by the phosphonic acid agents in vivo in the 6-day CAM 
assay involves induction of programmed cell death of 
microvascular endothelial cells. 
EXAMPLE 23 
Inhibition Effects of Phosphonic Acid Agents on Integrins 
and Human Microvascular Endothelial Cell Adhesion 
The adhesion receptor integrin, otv[33, has recently been 
identi?ed as a marker of angiogenic blood vessels in the 
chick chorioallantoic membrane and in humans (Brooks et 
al. 1994). It Was also apparent that this integrin played a very 
important role in angiogenesis. Topical application of a 
speci?c antibody against (otv[33 prevented the groWth of neW 
blood vessels in the chick CAM in response to cytokines and 
fragments of tumors (Brooks et al., 1994). In vitro, cell 
interaction With extracellular matrix has been shoWn to be 
related to induction of cell proliferation, motility, gene 
expression and programmed cell death (Ruoslahti and Reed, 
1994; Meredith et al., 1993). In fact, recent studies have 
shoWn that ligation of otv[33 on human endothelial cells in 
vitro promotes a rise in calcium and pH (Leavesley et al., 
1993), activation of focal adhesion kinase (De?llipi et al., 
1994) and the polymeriZation of the actin cytoskeleton 
(Sastry and HorWitZ, 1993), Which in turn regulates cellular 
shape and motility of endothelial cells on the extracellular 
matrix. These signaling events triggered by integrins prob 
ably play an important role in the functions and survival of 
microvascular endothelial cells undergoing angiogenesis. 
It has been shoWn that prevention of ligation of the otv[33 
integrin to the extracellular matrix promotes apoptosis of 
microvascular endothelial cells Which have been induced by 
angiogenic groWth factors to enter the cell cycle. After 
differentiation has occurred and mature blood vessels 
formed, integrin otv[33 signaling is no longer required for 
survival of the microvascular endothelial cells and they 
become refractory to the deleterious effects of the speci?c 
integrin antagonists. In conclusion, antagonists of integrin 
otv[33 disrupt neWly forming blood vessels Without affecting 
the preexisting vasculature (Brooks et al., 1994). 
We observed that cultures of human microvascular endot 
helial cells treated With suramin and more clearly With the 
phosphonic acid agents shoWed a large number of ?oating 
cells after 24 hr of treatment. Similar ?ndings Were reported 
by Pepper et al. (1994) With bovine microvascular endothe 
lial cells treated With suramin, and by Mitchen et al. (1993) 
With primary epithelial cell cultures from human prostate 
treated With suramin. When endothelial cells are cultured 
under conditions that prevent adhesion and spreading, they 
stop groWing, become detached, acquire a round cell shape 
and enter programmed cell death (Re et al., 1994). 
The regulation of integrin function by the urokinase 
receptor has also been reported (Wei et al., 1996), suggesting 
that reagents that affect the urokinase receptor can alter 
integrin function by disrupting the urokinase plasminogen 
receptor-integrin association representing potential thera 
peutic agents for tumor invasion and progression. The 
speci?c inhibition of the activity of the urokinase receptor 
mediated cell surface plasminogen activation system by 
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suramin and the direct effect of suramin on the cell surface 
associated With the urokinase receptor has already been 
shoWn (Behrendt et al., 1993; Ellis and Dano, 1993; Pepper 
et al., 1994). We postulate that the phosphonic acid agents 
might interfere With microvascular endothelial cell adhesion 
to the extracellular matrix, altering integrin functions, caus 
ing endothelial cell detachment and consequential induction 
of apoptosis. 
Cell attachment assay: The effects of the phosphonic acid 
agents in variable amounts (0—200 pM) on the interaction of 
human microvascular endothelial cells With components of 
the extracellular matrix, such as laminin (interacts With 
integrin (x261), ?bronectin (interacts With integrin (x561) 
and vitronectin (interacts With integrin otv[33), are studied as 
described by Sriramarao et al. (1993). Brie?y, different 
concentrations of the proteins (0—10 pig/ml) diluted in PBS 
are immobiliZed on 96 Well plates by incubating overnight 
at 4° C. The unbound sites are then blocked With serum free 
medium (MCDB-131 containing 1% BSA and 10 mM 
HEPES) by incubating the Wells for 1 hr at 37° C. The 
human microvascular endothelial cells are harvested after 
Washing With PBS and incubating the cells With a PBS 
based free enZyme free cell dissociation solution for 30 min 
at 37° C. The cell suspension are Washed With free serum 
medium and resuspended at 5><104 cells/ml and 100 pl are 
added to each Well. The plates are incubated for 1 hr at 37° 
C. For the anti-integrin antibody (used as positive control), 
the cells are preincubated for 30 min before being added to 
the protein coated Wells. Plates are Washed tWice With PBS 
containing 1 mM calcium and magnesium to remove 
unbound cells. The adherent cells are ?xed With 3.5% 
paraformaldehyde containing 0.5% crystal violet. Endothe 
lial cells are gently Washed and adherent cells quantitated by 
measuring the absorbance at 595 nm on a microtiter plate 
reader. 
Human microvascular endothelial cells treated With the 
active phosphonic acid agents shoW a decrease in the 
percentage of cells attached in relation to the controls. This 
effect is dose-related. Furthermore, We expect to see more 
signi?cant changes When the plates are coated With vitronec 
tin because its interaction With integrin otv[33 is inhibited by 
polyanions (Panetti et al., 1995). It takes longer than 12 hr 
for the detection of any suramin toxicity on endothelial cells 
even at concentrations higher than 200 pM. Hence, any 
effect observed in this short time incubation experiment can 
be interpreted as solely due to inhibition of cell attachment 
to the extracellular matrix by the phosphonic acid agents. 
EXAMPLE 24 
Effects of the Phosphonic Acid Agents on the Production of 
Protease by Human Microvascular Endothelial Cells In 
Vitro 
A tightly controlled increase in extracellular proteolysis, 
restricted both in time and space, is a very important 
component of the angiogenic process. This has led to the 
notion that compounds capable of inhibiting proteolysis 
could be effective in inhibiting angiogenesis (Pepper et al., 
1994). Indeed, protease inhibitors do inhibit angiogenesis 
and suramin has been shoWn to alter the proteolytic prop 
erties of bovine microvascular endothelial cells. Suramin 
has been shoWn to signi?cantly inhibit plasminogen activa 
tor activity induced by bFGF in fetal bovine aortic endot 
helial cells at concentrations higher than 250 pig/ml (Takano 
et al., 1994). These methods Were established in our labo 
ratory and used to study the effect of tamoxifen (a partial 
antiestrogen) on proteolytic properties of human microvas 
cular endothelial cells. These same methods are used to 
determine the effects of phosphonic acid agents. 
Human microvascular endothelial cells (HMEC-1 and 
HMVEC-d) are plated in 96 Well culture plates. After 24 hr, 
the medium are replaced With fresh MCDB-131 containing 
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5% FCS and varying amounts of the phosphonic acid agents. 
The experiment is carried out in the presence or absence of 
10 ng/ml bFGF. After 18—24 hr of incubation at 37° C. With 
5% COZ/air, the cells are Washed and lysed. Total protein is 
determined in the lysate and 1 pg of total protein is used to 
determine plasminogen activator (PA) activity With a chro 
mogenic method (American Diagnostica, Conn.) and With a 
microplate reader. Human urokinase (Calbiochem, La Jolla, 
Calif.) is used to generate the standard curve of PA activity. 
Results are expressed as the percentage of control activity. 
Zymographic analysis of PA is performed according to the 
method of Granelli et al. (1983). 
The phosphonic acid agents express inhibitory activity on 
the proteolytic properties in a dose-related manner. 
EXAMPLE 25 
Effect of the Phosphonic Acid Agents on Cell Matrix Matal 
loproteinases (MMPs) in the Endothelial Cells 
Matrix metalloproteinases are an important group of Zinc 
enZymes responsible for the degradation of the extracellular 
matrix components, such as collagen and proteoglycans. 
Currently, 16 family members have been identi?ed. MMP 
family member differ from each other structurally by the 
presence or absence of domains that contribute to activities 
such as substrate speci?city, inhibitor binding, matrix bind 
ing and cell surface localiZation (PoWell and Matrisian, 
1996). To determine if the phosphonic acid agents Were 
effective inhibitors of the MMP’s of endothelial cells, cells 
Were incubated in the presence of the different agents for 48 
hours. Tissue samples Were taken and subjected to Zymog 
raphy. Tissue samples Were placed in glass homogeniZers in 
a three fold Weight/volume of lysis buffer consisting of 50 
mM Tris-HCL, pH=7.4, With 200 mM sodium chloride and 
0.1% Triton X-100. The samples Were homogeniZed and 
centrifuged at 1500 g for 20 min. The supernatant Was 
immediately analyZed by Zymography. Protein content of 
each sample Was determined by a modi?ed LoWry method. 
MMP enZyme activity Was detected using polyacrylamide 
gel eltrophoresis Zymography. SDS-polyacrylamide gel 
electrophoresis (PAGE) Was performed using 8% acryla 
mide gels containing 0.1% gelatin. The volume of test 
samples loaded Was 15 pl. Electrophoresis Was run at 4° C. 
at a constant voltage (100 volts). After electrophoresis, gels 
Were incubated in Triton X-100 (2.5%) for 30 minutes to 
eliminate SDS, prior to being incubated overnight in 50 mM 
Tris HCL, pH7.5, containing 10 mM CaCl2 at 37° C. The 
gels Were stained in 0.25% (W/v) Coomassie Brilliant Blue 
and destained in methanolzacetic acid:Water (50:40:10). The 
clear Zones in these gels indicates the presence of proteins 
With gelatinolytic activity. This method alloWs for identi? 
cation of prometalloproteinases. Migration position of pro 
teins and With standard molecular Weight and supernatant 
from HT 1080 cells that express MMP-2 and MMP-9 Were 
used as controls. 
The results With human microvascular endothelial cells 
are as folloWs: NE 050, NE 162 and NE 681 are potent 
inhibitors of MMP-2 activity. bFGF increased MMP-2 activ 
ity in human microvacular endothelial cells and these phos 
phonic acid agents inhibited the increase in MMP-2 activity 
induced by bFGF. These results suggest that the MMP-2 in 
endothelial cells may be an important component in the 
angiogenesis process. This inhibition of MMP-2 by the 
phosphonic acid agents may be an important mechanism for 
the inhibition of angiogenesis. 
EXAMPLE 26 
Effect of the Phosphonic Acid Agents on Cell Matrix Met 
alloproteinases (MMP’s) in Cancer Cells In Vitro 
For a tumor cell to metastasiZe, it must break aWay from 
its neighbors and penetrate through the surrounding stoma 
and the basement membrane to enter the circulation. The 
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extensive degradation of the extracellular matrix component 
in tumor cells depends on the secretion of a battery of 
metalloendopeptidases that digest a Wide range of proteins 
of the extracellular matrix (Woessner, 1991). 
Several recent reports have shoWn a correlation betWeen 
MMP expression and tumor invasiveness in prostate cancer. 
Pajough et al. (1991) found that MMP-7 Was increased in 
malignant compared to benign prostatic tissue but absent in 
the stroma. Boag and Young (1993) found increased levels 
of gelatinase A (MMP-2) in malignant prostate and meta 
static tissue. Stearns and Wang (1993) analyZed prostrate 
cancer tissue extracts for gelatinase A (MMP-2) using 
Northern blot studies. Their results suggested that the 
enZyme is selectively overexpressed by malignant preinva 
sive epithelial cells With very loW levels in benign tissue and 
the stroma surrounding the tumor. Wilson et al. (1993) 
reported gelatinolytic proteinase activities in human prostate 
secretions, With an increased level of expression in neoplas 
tic compared to benign disease. The results presented by 
Hamdy et al. (1994) suggest that MMP-9 activity is 
increased in malignant compared to benign prostatic tissue. 
The gelatinase B (MMP-9) Was not expressed in benign 
tissue but Was detected in 42% of prostate carcinomas. 
Furthermore, those Who exhibited MMP-9 activity in vitro 
had particularly unfavorable clinical parameters, including 
Well-established prognostic factors, such as high Gleason 
scores, serum PSA levels and primary tumor ploidy. 
Furthermore, 100% of the patients that did not respond to 
treatment expressed MMP-9. 
Metalloproteinases have long been associated With 
metastasis and are major functional contributors to the 
metastatic process. MMP’s are important contributors to the 
initial groWth of metastasis, regulating access to groWth 
factors from the extracellular matrix and increasing angio 
genesis (Chambers and Matrisian, 1997). Activated MMP’s 
are susceptible to inhibition by the general serum proteinase 
inhibitor, ot-2-macroglobulin, and by a family of speci?c 
tissue inhibitors of metalloproteinases (TIMP). The tWo 
major members of this family, TIMP-1 and TIMP-2, are 
expressed by a variety of cell types. They form non 
covalent, stoichiometric complexes With both latent and 
active MMP. TIMP-1 is associated With progelatinase B and 
TIMP-2 is associated With progelatinase A. Malignant 
tumors many times exhibit complex patterns of expression 
of MMP’s and TIMP’s and therapeutic intervention might 
induce changes in this balance. 
Using the in vitro protocol described in EXAMPLE 25 
above, We have shoWn that the agents are potent inhibitors 
of MMP-9 activity in prostate cancer cells (PC-3) cells. 
MMP-2 activity is inhibited in DU-145 prostate cancer cell 
lines in vitro by the agents. This ?nding that the agents are 
potent inhibitors of MMP’s activity clearly indicates an 
important neW therapeutic function for the agents in cancer 
treatment. 
To determine if the phosphonic acid agents Were effective 
inhibitors of the MMP’s of prostate cancer cells (PC3 and 
DU-145), cells Were incubated in the presence of the dif 
ferent agents for 48 hours. Tissue samples Were taken and 
subjected to Zymography. Tissue samples Were placed in 
glass homogeniZers in a three fold Weight/volume of lysis 
buffer consisting of 50 mM Tris-HCL, pH=7.4, With 200 
mM sodium chloride and 0.1% Triton X-100. The samples 
Were homogeniZed and centrifuged at 1500 g for 20 minutes. 
The supernatant Was immediately analyZed by Zymography. 
Protein content of each sample Was determined by a modi 
?ed LoWry method. 
The expression of metalloproteinases 2 and 9 and tissue 
inhibitors of metalloproteinases (TIMP) 1 and 2 in human 
prostate tumor xenografts in nude mice is determined by the 
indirect immunoperoxidase method. Brie?y, tissue sections 
are deparaf?niZed by 100% xylene and then hydrated With a 
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graded series of ethanol. Frozen sections can also be uti 
liZed. The endogenous peroxidase is eliminated by incuba 
tion in 3% hydrogen peroxide for 30 minutes, and nonspe 
ci?c binding of IgG to tissue protein blocked by incubation 
With 100% normal rabbit serum for 1 hour. The sections are 
then reacted With monoclonal anti-human gelatinase A 
(MMP-2) or B (MMP-9) antibody raised in mouse 
(Oncogene Research Products, 4° C. overnight. Biotinylated 
anti-mouse antibody is used as the secondary antibody 
folloWed by peroxidase-strepavidin complex. The slides are 
rinsed three times With PBS after each tetrahydrochloride 
and hematoxylin used for nuclear staining. Negative con 
trols omitting either the primary or secondary antibodies are 
used for nonspeci?c staining. The ratio (%) of immunore 
active cells to total carcinoma cells is measured by counting 
cells in ?ve different ?elds at X200. TIMPS’s 1 and 2 are 
detected in froZen sections of the tumors using a monoclonal 
mouse antibody for human TIMP’s and the Mouse Unitect 
Immunohistochemistry detection kit (Oncogene Research 
Products, Cambridge, Mass.). 
EXAMPLE 27 
Effect of the Phosphonic Acid Agents on Endothelial Cell 
Migration In Vitro 
Suramin inhibits multiple control points of angiogenesis, 
such as angiogenic groWth factors binding to endothelial cell 
surface, endothelial cell migration, proliferation and produc 
tion of proteases (Coffey et al., 1987, Braddock et al., 1994, 
Pepper et al., 1994). Migration of microvascular endothelial 
cells is a key step in the angiogenesis process and appears to 
be more sensitive to suramin inhibition than does endothelial 
cell proliferation (Takano et al., 1994). Suramin signi?cantly 
inhibited endothelial cell migration determined by both the 
number of cells that migrated and the distance traveled by 
the cells from the Wound edge. The data con?rmed that 
suramin inhibits microvascular endothelial cell migration in 
concentrations above 150 pig/ml and that the phosphonic 
acid agents are much more potent inhibitors of endothelial 
cell migration than suramin (10 to 30 times). 
EXAMPLE 28 
Effect of the Phosphonic Acid Agents on Tube Formation in 
Endothelial Cells In Vitro 
Endothelial cell differentiation on Matrigel is a useful in 
vitro model for the study of certain steps in angiogenesis 
(Schnaper et al., 1993). The possibility that the phosphonic 
acid agents inhibit angiogenesis in vitro has been studied 
using Matrigel, a reconstituted matrix prepared from the 
Englebreth-Holm-SWarm (EHS) tumor extracellular matrix 
(Kleinman et al., 1982). When human umbilical vein endot 
helial cells or bovine microvascular endothelial cells Were 
seeded onto Matrigel, they formed a netWork of capillary 
like structures, mimicking the steps that occur during the 
formation of neW microvessels. Thus, the culture of endot 
helial cells on Matrigel serves as a useful model for the study 
of endothelial cell activity during in vitro angiogenesis. 
Although there is a dramatic morphologic change in 
endothelial cell population involving cell elongation, anas 
tomosis and branching, gene transcription and translation 
are not required for the regulation of this process (Zimrin et 
al., 1995). Rather, post-translation-al events are involved 
since the Matrigel-dependent process could be inhibited by 
addition of a protein kinase inhibitor. 
To measure the effect of the phosphonic acid agents on the 
ability of tube formation by human microvascular endothe 
lial cells, 200 pl of Matrigel is plated on a 24 Well culture 
plates. After the Matrigel is alloWed to gel for 30 min at 37° 
C., 40,000 cells (previously groWn on plastic dishes) in 1 ml 
MCDB-131 medium is plated onto the Matrigel. After 18 
and 24 hr, the cultures are ?xed, stained and the area of tubes 
formed on the surface of the Matrigel are quantitated using 
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an image analysis system (Loats Associates, Inc., 
Westminster, Md.). Additional experiments need to be car 
ried out in the presence of various amounts of PMA (40—200 
ng/ml) to determine if the inhibitory effect of the phosphonic 
acid agents can be overcome by the stimulation of PKC With 
a phorbol ester. 
The phosphonic acid agents inhibit tube formation in a 
dose-dependent manner and that stimulation of PKC by the 
phorbol ester might overcome the inhibition. 
EXAMPLE 29 
Antiangiogenic Effects of the Phosphonic Acid Agents 
Expressed in an In Vivo Mammalian (Mouse) Model of 
Angiogenesis 
The phosphonic acid agents inhibit angiogenesis in a 
simple and rapid in vivo model that alloWs the ready 
quantitative assessment of angiogenic and antiangiogenic 
factors. The method developed by Passaniti et al. (1992) 
consists of subcutaneously injecting mice With bFGF 
embedded in Matrigel in the presence of heparin. Subcuta 
neous injection of Matrigel plus bFGF and heparin at the 
ventral midline achieved optimal and reproducible 
responses. Sprouts from vessels in the adjacent tissue pen 
etrated the gel Within 2 days, connecting it With the external 
vasculature and reaching a plateau after 4 days, and persisted 
up to 8 days. Matrigel forms a solid gel When injected into 
mice and support a rapid and intense angiogenic reaction in 
the presence of heparin and bFGF. Matrigel has been used to 
promote differentiation of endothelial cells into capillary 
structures in culture, and When utiliZed as a vehicle in vivo, 
may enhance the selectivity of endothelial cells entering the 
gel since basement membranes are not readily crossed by 
?broblasts and other cells. Gels supplemented With bFGF 
and heparin induced intense vasculariZation. The site of 
injection and the age of the mice can affect the magnitude of 
the observed angiogenic response. Angiogenesis is quanti 
tated by image analysis of vessels and by measuring the 
hemoglobin present in the vessels Within the gel. 
This approach is used to determine Whether the selected 
phosphonic acid agents can inhibit angiogenesis in vivo 
using C57B1/6 mice (6 months old). All mice are treated on 
day 1 of the experimental protocol by injection of 0.2 ml of 
Matrigel With a dose of heparin plus bFGF shoWn to induce 
intense angiogenesis. The animals are also treated i.p. daily 
With 2.0, 0.2 and 0.05 nmoles/20 gram body Weight of 
phosphonic acid agents shoWn to be active antiangiogenic 
compound in the CAM and HMECl all in vitro. The control 
group receives daily i.p. injections of physiological saline. 
After ?ve days of treatment, the mice are euthaniZed and 
dissected. Photographs are taken of the area around the 
Matrigel implants and the gel is removed along With a 
section of the peritoneal lining for support, typically the 
overlying skin. The Drabkin method (Drabkin reagent kit 
525, Sigma, St Louis, M0.) is used to measure hemoglobin 
levels in the implants. Protein content of the supernatant 
?uid is determined using the BioRad protein assay method. 
All specimens are ?xed in 10% buffered formalin for at least 
24 hr, dehydrated, embedded in paraf?n and sectioned at 5 
micron thickness, deparaf?niZed, and stained With hema 
toxylin and eosin. Selected sections are stained for Factor 
VIII-related antigen using an immunoperoxidase method. To 
measure the total area of neovessels, a computeriZed 
digitalyZer, the Optomax image analysis system (Optomax), 
is used. 
The model described by Passaniti et al. (1992) is used as 
it gives ready quantitative assessment of angiogenesis and is 
reliable and shoWn to be useful in testing biological factors 
and drugs that regulate angiogenesis. Suramin is an effective 
inhibitor of angiogenesis in vivo as described by Pesenti et 
al. (1992). Furthermore, the active phosphonic acid agents 
are 10 to 30 times more active than suramin in inhibiting 
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angiogenesis. Moreover, a direct correlation is found 
between the potency of inhibition of angiogenesis in the 
CAM assay and in the mouse model for the phosphonic acid 
analogues. 
EXAMPLE 30 
The compounds of the present invention are useful in 
pharmaceutical compositions for systemic administration to 
humans and animals in unit dosage forms, such as tablets, 
capsules, pills, poWders, granules, suppositories, sterile 
parenteral solutions or suspensions, sterile non-parenteral 
solutions or suspensions oral solutions or suspensions, oil in 
Water or Water in oil emulsions and the like, containing 
suitable quantities of an active ingredient. Topical applica 
tion can be in the form of ointments, creams, lotions, jellies, 
sprays, douches, and the like. For oral administration either 
solid or ?uid unit dosage forms can be prepared With the 
compounds of Formula I. The compounds are useful in 
pharmaceutical compositions (Wt %) of the active ingredient 
With a carrier or vehicle in the composition in about 1 to 20% 
and preferably about 5 to 15%. 
Either ?uid or solid unit dosage forms can be readily 
prepared for oral administration. For example, the com 
pounds can be mixed With conventional ingredients such as 
dicalciumphosphate, magnesium aluminum silicate, magne 
sium stearate, calcium sulfate, starch, talc, lactose, acacia, 
methyl cellulose and functionally similar materials as phar 
maceutical excipients or carriers. A sustained release for 
mulation may optionally be used. Capsules may be formu 
lated by mixing the compound With a pharmaceutical diluent 
Which is inert and inserting this mixture into a hard gelatin 
capsule having the appropriate siZe. If soft capsules are 
desired a slurry of the compound With an acceptable 
vegetable, light petroleum, or other inert oil can be encap 
sulated by machine into a gelatin capsule. 
Suspensions, syrups and elixirs may be used for oral 
administration of ?uid unit dosage forms. A ?uid preparation 
including oil may be used for oil soluble forms. Avegetable 
oil such as corn oil, peanut oil or saf?oWer oil, for example, 
together With ?avoring agents, sWeeteners and any preser 
vatives produces an acceptable ?uid preparation. A surfac 
tant may be added to Water to form a syrup for ?uid unit 
dosages. Hydro-alcoholic pharmaceutical preparations may 
be used having an acceptable sWeetener such as sugar, 
saccharine or a biological sWeetener and a ?avoring agent in 
the form of an elixir. 
Pharmaceutical compositions for parenteral and supposi 
tory administration can also be obtained using techniques 
standard in the art. 
Another preferred use of the compounds is in a transder 
mal parenteral pharmaceutical preparation in a mammal 
such as a human. Accordingly, compositions suitable for 
administration to these areas are particularly included Within 
the invention. The above parenteral solutions or suspensions 
may be administered transdermally and, if desired a more 
concentrated sloW release form may be administered. 
Accordingly, incorporation of the active compounds in a 
sloW release matrix may be implemented for administering 
transdermally. The compounds may be administered trans 
dermally at about 1 to 20% of the composition and prefer 
ably about 5 to 15% Wt % of the active ingredient in the 
vehicle or carrier. 
Transdermal therapeutic systems are self-contained dos 
age forms that, When applied to intact skin, deliver drug(s) 
at a controlled rate to the systemic circulation. Advantages 
of using the transdermal routing include: enhanced thera 
peutic efficacy, reduction in the frequency of dosing, reduc 
tion of side effects due to optimiZation of the blood 
concentration versus time pro?le, increased patient 
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compliance due to elimination of multiple dosing schedules, 
bypassing the hepatic “?rst-pass” metabolism, avoiding 
gastrointestinal incompatibilities and providing a predict 
able and extended duration of activity. HoWever, the main 
function of the skin is to act as a barrier to entering 
compounds. As a consequence, transdermal therapy has so 
far been restricted to a limited number of drugs that possess 
the desirable physiochemical properties for diffusion across 
the skin barrier. One effective method of overcoming the 
barrier function of the skin is to include a penetration 
enhancer in the formulation of a transdermal therapeutic 
system. See Barry, Brian W.: Dermatological Formulations: 
Percutaneous Absorption (Dekker, NY, 1983); Bronough et 
al, Percutaneous Absorption, Mechanisms-Methodology 
Drug Delivery, (Marcel Dekker, NeW York, NY. 1985); and 
Monkhouse et al, Transdermal drug deliver-problems and 
promises. Drug Dev. Ind. Pharm., 14, 183—209 (1988). 
A penetration enhancer is a chemical compound that, 
When included in a formulation, temporarily increases the 
permeability of the skin to a drug alloWing more of the drug 
to be absorbed in a shorter period of time. Several different 
types of penetration enhancers have been reported such as 
dimethylsulfoxide, n-decyl methyl sulfoxide, N,N 
dimethylacetamide, N,N-dimethylformamide, 
1-dodecylaZacycloheptan-2-one (AZone), propylene glycol, 
ethanol, pyrrolidones such as N-methyl-2-pyrrrolidone 
(NMP) and surfactants. See Bronough et al, supra, and 
Stoughton et al, AZone: a NeW Non-toxic enhancer of 
percutaneous penetration. Drug Dev. Inc. Pharm., 9, 
725—744 (1983). 
N-methyl-2-pyrrolidone is a versatile solvent Which is 
miscible With Water, ethyl alcohol, ether, chloroform, 
benZene, ethyl acetate and carbon disul?de. 
N-methylpyrrolidone has been Widely used as a solvent in 
industrial processes such as petroleum re?ning, GAF Corp.: 
“M-Pyrol (N-methyl-2-pyrrolidone) Handbook.”, GAF 
Corp., NeW York, 1972. It is currently used as a solubiliZing 
agent in topical and parenteral veterinary pharmaceuticals 
and is noW under consideration for use in products intended 
for humans, Wells, D. A. et al: Disposition and Metabolism 
of Double-Labeled [3H and 14C] N-methyl-2-pyrrolidone in 
the Rat. Drug Met. Disps., 16, 243—249 (1988). Animal and 
human experiments have shoWn very little irritation or 
sensitiZation potential. Ames type assays and chronic expo 
sure studies have not revealed any signi?cant toxicity, Wells 
et al, Mutagenicity and Cytotoxicity of N-methyl-2-p 
[yrrolidone and 4-(methyl amino) Butanoic Acid in the 
Salmonella/microsome Assay. J. Appl. T0x., 8, 135—139 
(1988). N-methylpyrrolidone has also been shoWn to be an 
effective penetration enhancer. Barry et al, OptimiZation and 
Bioavailability of Topical Steroids: Penetration Enhancers 
Under Occlusion. J. Inv. Derm, 82, 49—52 (1984); Akter et 
al, Absorption Through human Skin of Ibuprofen and Flur 
biprofen; Effect of Dose Variation, Deposited Drug Films, 
Occlusion and the Penetration Enhancer N-methyl-2 
pyrrolidone. J. Pharm. PharmacoL, 37, 27—37 (1984); Hole 
gaard et al, Vesical Effect on Topical Drug Delivery IV. 
Effect of N-methylpyrrolidone and Polar Lipids on Percu 
taneous Transport. Int. J. Pharm., 43, 233—240 (1988); 
Sugibayashi et al, Effect of Several Penetration Enhancers 
on the Percutaneous Absorption of Indomethacin in Hairless 
Rat. Chem. Pharm. BulL, 36, 1519—1529 (1988); Bennett et 
al, OptimiZation of Bioavailability of Topical Steroids: Non 
occluded penetration Enhancers Under Thermodynamic 
Control. J Pharm. PharmacoL, 37, 298—304 (1985); Sasaki 
et al, Enhancing Effect of Pyrrolidone Derivatives on Trans 
derman Drug Delivery. 1. Ing. J. Pharm., 44, 14—24 (1988); 
Lee et al, Toxicity of N-methyl-2-pyrrolidone (NMP): 
Teratogenic, Subchronic and TWo-year Inhalation Studies, 
Fund. AppL, T0x., 9, 222—235 (1987). 
The above and other drugs can be present in the reservoir 
alone or in combination form With pharmaceutical carriers. 
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The pharmaceutical carriers acceptable for the purpose of 
this invention are the art known carriers that do not 
adversely affect the drug, the host, or the material compris 
ing the drug delivery device. Suitable pharmaceutical car 
riers include sterile Water; saline, dextrose; dextrose in Water 
or saline; condensation products of castor oil and ethylene 
oxide combining about 30 to about 35 moles of ethylene 
oxide per mole of castor oil; liquid acid; loWer alkanols; oils 
such as corn oil; peanut oil, sesame oil and the like, With 
emulsi?ers such as mono- or di-glyceride of a fatty acid, or 
a phosphatide, e.g., lecithin, and the like; glycols; polyalky 
lene glycols; aqueous media in the presence of a suspending 
agent, for example, sodium carboxymethylcellulose; sodium 
alginate; poly(vinylpyrolidone); and the like, alone, or With 
suitable dispensing agents such as lecithin; polyoxyethylene 
stearate; and the like. The carrier may also contain adjuvants 
such as preserving stabiliZing, Wetting, emulsifying agents 
and the like together With the penetration enhancer of this 
invention. 
The effective dosage for mammals may vary due to such 
factors as age, Weight activity level or condition of the 
subject being treated. Typically, an effective dosage of a 
suramin compound is about 12 g administered for 6 Weeks 
(NCI). The phosphonic acid agents may be administered in 
a dosage of about 3 g for 6 Weeks. 
Compounds of the present invention may be administered 
topically at about 1 to 20 Wt % of the composition, and 
preferably about 5 to 15 Wt %. Suramin is presently given by 
sterile iv. injection because of the poor absorption from the 
gut. For suramin treatment of prostate cancer (Stein 1989), 
suramin is given iv. (1—2 g/Wk) for a 6 Week treatment 
period. The chemical characteristics of the phosphonic acid 
agents suggest that higher effective dosages are achievable. 
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